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Homeostasis of the hematopoietic stem/progenitor cell pool relies on a finely tuned 
balance between self-renewal, differentiation and proliferation. Recent work has 
revealed the importance of mitochondria during stem cell differentiation; however, it 
remains unclear whether mitochondrial content/function affects human hematopoietic 
stem versus progenitor function. We sorted cord blood-derived CD34+ cells on the basis 
of mitochondrial mass and examined their homeostasis and clonogenic potential in vitro 
and hematopoietic repopulation potential in vivo. CD34+ cells with high mitochondrial 
mass contained and expressed 2-fold high ATP levels and mitochondrial-specific genes 
than cells with low mitochondrial mass, however, HIF-1α and MEIS1 were high in the 
CD34+ cells with low mitochondria. We found that CD34+ cells with low mitochondrial 
content were enriched for hematopoietic stem cell function as demonstrated by 
significantly higher hematopoietic reconstitution potential in immunodeficient mice. 
By contrast, CD34+ cells with high mitochondrial content were enriched for 
hematopoietic progenitor function with high in vitro clonogenic capacity.  
Coenzyme Q10 (CoQ10) plays a critical role in mitochondria as an electron carrier 
within the electron transport chain (ETC) and is an essential antioxidant. Mutations 
in genes responsible for CoQ10 biosynthesis (COQ genes) cause primary CoQ10 
deficiency, a rare and heterogeneous mitochondrial disorder with no clear 
genotype-phenotype association, mainly affecting tissues with high energy demand 
including brain and skeletal muscle (SkM). A four-year-old girl was identified with 
a heterozygous mutation (c.483G>C; E161D) in COQ4, associated with a reduction 
in [CoQ10], CoQ10 biosynthesis and ETC activity affecting complexes I/II+III. 
Bona fide induced pluripotent stem cell (iPSC) lines carrying the COQ4 mutation 
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(CQ4-iPSCs) were generated, characterized and genetically corrected using 
CRISPR/Cas9 genome-editing (CQ4ed-iPSCs). Comprehensive differentiation and 
metabolic analysis of control-iPSCs, CQ4-iPSCs and CQ4ed-iPSCs faithfully 
reproduced the disease phenotype. Accordingly, the COQ4 mutation in iPSCs was 
associated with CoQ10 deficiency, metabolic dysfunction and impaired 
differentiation into SkM. Remarkably, differentiation of CQ4-iPSCs into 
dopaminergic or motor neurons was unaffected. This study offers an unprecedented 
iPSC model recapitulating CoQ10 deficiency-associated functional and metabolic 
phenotypes caused by COQ4 mutation.  
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ADP Adenosine diphosphate 
AGM Aorta-gonad-mesonephros 
ALS Amyotrophic lateral sclerosis 
ATP Adenosine triphosphate 
BM Bone marrow 
CB Cord blood 
CI Complex I or NADH-coenzyme Q oxidoreductase 
CII Complex II or Succinate-Q oxidoreductase 
CIII Complex III or coenzyme Q-cytochrome c oxidoreductase 
CIV Complex IV or Cytochrome c oxidase 
CNS Central nervous system 
CRISPR Clustered regularly interspaced short palindromic repeats 
DAn Dopaminergic neurons 
DNA Deoxyribonucleic acid 
DSB Double-strand break 
ECAR Extracellular acidification rate 
ESC Embryonic stem cell 
ETC/ MRC Electron transport chain/ Mitochondrial respiratory chain 
FAD Flavin adenine dinucleotide 
HDR Homology direct repair 
HPC Hematopoietic progenitor cell 
HSC Hematopoietic stem cell 
HSPC Hematopoietic stem/progenitor cell 
IDH1 Isocitrate dehydrogenase 1 
IDH2 Isocitrate dehydrogenase 2 
iPSC Induced pluripotent stem cell 
KDH α-ketoglutarate dehydrogenase  
LT-HSC Long-term hematopoietic stem cell 
II
 
Damià  
Romero Moya 
 
22 
MMP Mitochondrial membrane potential 
MN Motor neurons 
mtDNA Mitochondrial DNA 
NAD Nicotinamide adenine dinucleotide 
NGPS Néstor-Guillermo progeria syndrome 
NHEJ Non-homologous end joining 
NSC Neural stem cell 
OCR Oxygen consumption rate 
OXPHOS Oxidative phosphorylation 
PDH Pyruvate dehydrogenase  
RNA Ribonucleic acid 
ROS Reactive oxygen species 
SC Stem cell 
sgRNA Small guide RNA 
SkM Skeletal muscle 
ST-HSC Short-term hematopoietic stem cell 
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III.1.STEM CELLS: DEFINITION, CLASSIFICATION 
AND LOCALIZATION 
Stem cells (SCs) are immature and undifferentiated cells with both self-renewal and 
multilineage potential. Self-renewal, which is the ability to undergo symmetrical 
division while preserving multilineage potential [1, 2] is maintained by a balance 
between symmetric and asymmetric cell division, whereby daughter cells produce one 
cell identical to the progenitor and another cell which undergoes differentiation 
(asymmetric division) or produce two cells identical to the progenitor (symmetric 
division) (Figure 1). Multilineage potential or potency, a hallmark of SCs, is the ability 
to differentiate into other cell types. Accordingly, the more cell types the cell can give 
rise to the greater is the potency [2]. 
 
 
FIGURE 1: Schematic representation of the 
balance between symmetric and asymmetric 
division. Symmetric division expands the stem cell 
pool and allows a cell to self-renew and maintain 
its status, while asymmetric division maintains the 
stem cell pool and also creates a committed cell. A: 
Stem cell; B: Progenitor cell; C: Differentiated 
cell; 1: Symmetric stem cell division; 2: 
Asymmetric stem cell division; 3: Progenitor 
division; 4: Terminal differentiation.   
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This differentiation potency forms the core of a classification system whereby SCs can 
be ordered based on their multilineage potency as follows: (see Figure 2)  
- Totipotent SCs: are cells with the potential to differentiate into any embryonic 
and extraembryonic tissue. Totipotent SCs have the greatest differentiation 
potential and can generate a complete organism. In mammals this cell type is 
the zygote [2]. 
- Pluripotent SCs: are the next cells to appear during embryonic development. 
Pluripotent SCs can differentiate into almost all cell types and generate any 
tissue of the three embryonic germ layers (endoderm, mesoderm and 
ectoderm). However, they have lost the capacity to differentiate into 
extraembryonic tissue. An example of a pluripotent cell would be the 
discovery of human embryonic stem cells (ESCs) derived from the inner cell 
mass of a blastocyst, reported for the first time by Thomson et al. in 1998 [3]. 
ESCs can proliferate indefinitely while maintaining pluripotency. In 2007, 
Takahashi et al. induced the pluripotent state from human somatic cells using 
a cocktail of specific transcription factors, thus establishing induced 
pluripotent stem cells (iPSCs), which display similar capacity to proliferate 
and differentiate to ESCs [2, 4, 5]. 
- Multipotent SCs: are cells with the ability to differentiate into most cell types 
of a specific tissue. In humans, several types of tissue-specific multipotent SCs 
have been described e.g., neural stem cells (NSCs) [6], hematopoietic stem 
cells (HSCs) [7], and mesenchymal stem cells (MSCs) [8]. 
- Oligopotent SCs: are cells that can differentiate into only a few cell types of a 
given tissue. In the hematopoietic system, common lymphoid progenitors 
II
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(CLPs) and common myeloid progenitors (CMPs) are representative of 
oligopotent SCs [7]. 
- Unipotent SCs: can only produce their own cell type. They are located in adult 
tissues and play a key role in tissue homeostasis. Muscle and epidermial SCs 
are examples of unipotent cells.  
 
SCs are acknowledged as a potentially powerful tool for cell therapy and regenerative 
medicine applications. Furthermore, the differentiation of SCs into tissue-specific 
lineages has aided in the elucidation of key biological process during development and 
is a promising platform for disease modeling [9]. Below, we describe the SC 
populations utilized in the present work.  
FIGURE 2: Schematic representation of different types of SCs based on their potency. A 
totipotent SC is represented by the zygote. Pluripotent SCs include ESCs and iPSCs. 
Multipotent SCs are tissue-specific SCs such as HSCs, MSCs, NSCs, etc.  
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III.1.1.INDUCED PLURIPOTENT STEM CELLS 
iPSCs were generated for the first time in 2006 in a pioneering study using retroviruses 
to ectopically express defined pluripotency-associated transcription factors in 
embryonic and adult mouse cells [10]. One year later, the same group generated human 
iPSCs in a similar approach using the transcription factors OCT3/4, SOX2, KLF4 and 
C-MYC (OSKM), colloquially known as “Yamanaka factors” [5] (Figure 3). iPSCs are 
generated by direct transcriptomic, epigenetic and metabolic reprogramming of somatic 
cells and behave like ESCs with regards to pluripotency and self-renewal. Since the 
first descriptions of iPSCs, many reports have reviewed the similarities and differences 
between iPSCs and ESCs with contentious results. Several groups reported that despite 
sharing similar pluripotency capacity, iPSCs differ from ESCs by their epigenetic 
memory of somatic origin [2, 11-13]. However, other groups have demonstrated that 
no such differences exist [2, 14]. In the 10 years since its first description, a broad 
variety of somatic cells have been successfully reprogrammed using different 
combinations of genes and/or small molecule inducers [15-21]. The relative ease with 
which iPSCs are generated has led to their wide use in developmental biology, disease 
modeling, drug testing and also cell therapy (Figure 4) [9]. 
 
FIGURE 3: Representative scheme of somatic cell reprogramming (iPSC generation) after 
transgene (OSKM) transduction. Modified from the National Institutes of Health. 
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Bona fide characterization of pluripotency is crucial after iPSC generation to confirm 
their identity [22]. Transgene expression has to be silenced shortly after iPSC 
generation; the inability to silence the ectopic expression of the Yamanaka factors 
makes iPSCs transgene-dependent, thus preventing subsequent differentiation [23]. 
Because chromosomal alterations can occur during the reprogramming process, a key 
test to ensure that iPSCs have a diploid karyotype is to assess genome stability by G-
banding (as a minimum). Moreover, pluripotency-specific cell surface markers, such as 
SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and transcription factors including OCT-3/4, 
NANOG, SOX2, REX1, CRIPTO, among others, have to be expressed in iPSCs. 
Teratoma formation in immunodeficient mice is the most stringent functional assay and 
the gold standard to define bona fide iPSCs [22]. While the first gene delivery methods 
used to reprogram somatic cells were traditional integrative vectors, such as lentivirus 
or retrovirus [24], more recently non-integrative methods such as Sendai virus [15] or 
FIGURE 4: Schematic representation of the potential utility of iPSCs in regenerative 
medicine and drug screening. Introduction of reprogramming factors into a patient’s somatic 
cells give rise to iPSCs. These iPSCs can then be differentiated into a variety of specialized 
cell types for potential use in disease modeling or cell therapy. Modified from [9]. 
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episomal vectors, as well as epigenetic modifiers/compounds [21], have been used 
successfully to deliver reprogramming factors [24]. 
ESCs and iPSCs hold great promise in cell therapy and regenerative medicine. The 
successful prospective differentiation of iPSCs into tissue/lineage-specific cells will 
render cell populations of potential clinical value. The utility of iPSC-derivatives relies 
on the ability to generate functional and homogeneous cell subsets for transplantation. 
In hematopoietic tissue, functional HSCs with long-term hemato-immune engraftment 
potential have not yet been reported [9, 25, 26]. This may be due to the fact that 
additional, yet unknown, intrinsic factors and/or extrinsic signals are required for the 
generation of in vivo long-term hematopoietic reconstitution [25]. By contrast, several 
studies have demonstrated the capacity of iPSC-derived neurons to engraft in 
experimental animal models [27-29]. Several clinical trials using iPSC- and ESC-
derivatives are ongoing. No side effects thus far have been reported in these preliminary 
trials, and some degree of success has been found with retinal pigment epithelium [30], 
cardiac progenitors [31] and pancreatic endoderm cells [32], among other lineages. The 
current status of pluripotent SC applications in the clinic has been recently reviewed by 
Kimbrel et al. [33]. 
Recent publications have demonstrated that human iPSCs can be grown under standard 
conditions in the primed state or grown in the naïve state [34, 35]. Primed iPSCs retain 
the gene expression and methylation profile of the tissue from which they were derived, 
whereas naïve iPSCs, regardless of their cellular origin, share a similar transcriptional 
and epigenetic profile. However, when naïve iPSCs revert to the primed state, 
surprisingly they re-establish their original transcriptomic and epigenetic profile, 
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suggesting epigenetic memory [13]. Importantly, the differentiation capacity of iPSC 
lines is influenced by genetic and epigenetic variability [13, 36, 37], presumably 
reflecting their cellular origin, the genetic background and the different reprogramming 
strategies. To rule out the variability among different iPSCs, isogenic iPSCs should be 
used for disease modeling studies. Accordingly, pairs of iPSC lines can be engineered 
with only one specific modification by genome editing strategies against an otherwise 
isogenic background. Among the different techniques available, Zinc Finger Nuclease 
(ZFN), Transcription Activator-Like Effector Nucleases (TALENs), Clustered 
Regularly Interspaced Short Palindromic Repeat/Cas9 (CRISPR/Cas9) and Helper-
Dependent Adenoviral Vectors (HDAdVs) are those most commonly used to correct 
and/or edit the monogenic mutations to generate isogenic iPSC pairs for disease 
modeling [38, 39]. 
III.1.2.HEMATOPOIETIC STEM CELLS AND HEMATOPOIESIS 
HSCs are multipotent SCs that emerge early during development and maintain 
hematopoiesis throughout the entire lifespan of the organism [40]. Human 
hematopoiesis is a complex process involving several organs during development. The 
definitive HSC emerges first in the aorta-gonad-mesonephros (AGM) region [41, 42], 
and then migrates to liver and placenta. The fetal liver is the principal hematopoietic 
organ during development. Later, the spleen, thymus and lymphatic nodes are colonized 
by HSCs, which further migrate to the bone marrow (BM) where they reside throughout 
the lifetime of the organism (Figure 5) [40, 42, 43]. 
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Hematopoiesis is a hierarchical process where the most immature cells (HSCs) reside 
at the apex and undergo several stages of differentiation to generate a variety of mature 
blood cells. HSCs, hematopoietic progenitor cells (HPCs), lineage committed cells 
(myeloid or lymphoid) and mature cells can be phenotypically and functionally 
distinguished (Figure 6). Hematopoietic stem/progenitor cells (HSPCs) are almost 
exclusively enriched in the CD34+ fraction, which represents a small population (<1%) 
in cord blood (CB) and BM [44, 45]. Phenotypically, human HSCs are enriched in the 
Lin-CD34+CD38- fraction and HPCs are enriched in the Lin-CD34+CD38+ fraction. 
Functionally, HSCs are the only cells able to complete hematopoietic engraftment after 
HSPC transplantation. Within the HSC fraction are Long-Term HSCs (LT-HSCs), 
which are responsible for durable hematopoietic engraftment, and Short-Term HSCs 
(ST-HSCs), which ensure short-term reconstitution. Consequently, HPCs have a lower 
reconstitution capacity due to lineage commitment [7, 44]. Hematologic malignancies 
FIGURE 5: Human embryonic blood development: primitive hematopoiesis starts in the 
yolk sac by day 17. Definitive hematopoiesis starts in the AGM region, and by day 30 
migrates to the fetal liver. The BM is the last and definitive niche for HSCs. Modified from 
[43]. 
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and severe immunodeficiencies are target diseases for HSPC transplantation. Umbilical 
CB has been extensively used as a source of HSPCs since the 1980s as it represents a 
unique source of HSPCs due to its high percentage of CD34+ cells and low 
immunogenicity [46, 47]. In the setting of clinical transplantation, the dose of total 
CD34+ cells infused per kg of the patient’s bodyweight is used as a predictor of short-
term hematopoietic recovery and establishment of long-term engraftment [44, 48]. 
FIGURE 6: Developmental hierarchy of hematopoiesis: LT-HSC and ST-HSC are Lin
-
CD34
+
CD38
-
. HPC comprise multipotent progenitors (MPP), common myeloid 
progenitors (CMP) and common lymphoid progenitors (CLP) and are Lin
-
CD34
+
CD38
+
.  
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Initially, CB transplantation was restricted to children or low-weight adults due to the 
limited number of HSPCs. Over the last years, however, different strategies have been 
implemented to improve CB transplantation efficacy, including CB-derived CD34+ cell 
expansion, ex vivo and in vivo homing techniques, or double CB administration [49].  
BM stem cell niche is functionally defined as a specialized cellular structure which is 
essential for long-term maintenance of adult HSCs. The balance between quiescence 
and self-renewal is most probably regulated by dynamic reciprocal interaction between 
single HSCs and their niches [50]. Stem cells are regularly distributed either in 
quiescent or cycling states. The majority of LT-HSCs are in a quiescence, which is 
accompanied by low metabolic activity, as a mechanism for avoiding accumulation of 
DNA damage, and necessary to preserve the self-renewal capacity of HSCs and to 
prevent stem cell exhaustion. Despite their quiescence, HSCs exhibit the highest self-
renewal potential of all blood cells [51, 52]. HSCs and HPCs are identified in vivo and 
in vitro based on the expression of cell surface markers [53] or by their unique 
metabolic profiles [51, 54-56]. Simsek et al. defined the metabolic phenotype of mouse 
HSCs, demonstrating that HSC are enriched in a distinct population of cells 
characterized by low mitochondrial potential (i.e., mitochondrial membrane potential 
or MMP, ATP and oxidative phosphorylation or OXPHOS). The metabolic phenotype 
of LT-HSC confers them a survival advantage in both physiological hypoxic or anoxic 
BM niche [57, 58]. Under hypoxic conditions, glycolytic metabolism predominates, 
providing sufficient amounts of ATP to sustain HSCs. Glycolysis allows ATP 
generation with limited reactive oxygen species (ROS) production, being a less efficient 
but safer cellular process. The transcription factor hypoxia-inducible factor-1 (HIF-1) 
plays an essential role in the maintenance of oxygen homeostasis. HIF-1 is a 
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heterodimeric protein that comprises two subunits: HIF-1α, which is stabilized by 
hypoxia, and HIF-1β, which is constitutively expressed [59]. HIF-1 is a master 
regulator of the transcriptional response to hypoxia and induce the expression of 
glycolytic enzymes, allowing the production of energy when mitochondria are starved 
of oxygen. HIF-1 is thus considered the key protein responsible for the metabolic 
adaptation to hypoxia [60-63].  
III.1.3.NERVOUS TISSUE 
Mammalian nervous tissue is composed by the central nervous system (CNS) and the 
peripheral nervous system, which regulates body functions and activity. The CNS is 
largely made up by two types of cells: neurons and glial cells. Neurons are excitable 
cells that transmit information, whereas glial cells have a basically supportive function. 
The adult nervous system has classically been considered incapable of generating new 
neurons because they are post-mitotic and do not divide. However, this view was 
changed by the discovery of brain neurogenesis and the existence of NSCs in the adult 
mammalian brain [6, 64].  NSCs are self-renewing multipotent progenitors that give 
rise to neurons, astrocytes and oligodendrocytes in the CNS (Figure 7). Neurogenic 
niches within the adult CNS are well characterized and are localized to the 
subventricular zone, the subgranular zone and the carotid body [6, 65]. NSCs isolated 
at different developmental stages share expression of NESTIN, MUSASHI, NCAM 
and SOX2. The expression of the majority of these markers is regulated during the 
initial phases of neural induction and is then maintained in NSCs throughout ontogeny 
[66].  
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Every region in the brain possesses its own type of neurons, which differ in their 
morphology, connectivity and electrophysiological properties. Although the function 
of some of these neurons has yet to be determined, recent work has enabled their 
classification based on RNA expression [67]. Two of the most well characterized types 
of neurons are dopaminergic neurons (DAns) and motor neurons (MNs) due to their 
dysfunction in Parkinson disease and amyotrophic lateral sclerosis (ALS), respectively, 
which are common neurodegenerative diseases. Midbrain DAns are located in three 
major nuclei (A8, A9 and A10) [68, 69] that originate from the ventricular zone in the 
ventral midbrain and produce the neurotransmitter dopamine. OTX2, FOXA2 and 
LMX1α cooperate to enhance dopaminergic commitment [70-72] by inducing the 
expression of several specific transcription factors such as PITX3, NURR1, EN1/2 and 
TH, among others [68, 69, 73]. MNs can originate in the cerebral cortex (upper MNs) 
or in the brainstem and spinal cord (lower MNs), and control directly or indirectly the 
effector organs e.g., muscle [74]. Early in development, retinoic acid (RA) is crucial 
FIGURE 7: Representative 
human neural hierarchy: Neural 
stem cells have self-renewal 
capacity and can differentiate 
into two different progenitors: 
neuronal restricted progenitors 
and glial restricted progenitors.  
II
I 
Mitochondria and stem cell function: 
from somatic cells to iPSC-based disease modeling 
  37 
 
for the initial distinction of neurons of the hindbrain and spinal cord. Next, a sonic 
hedgehog (SHH) gradient regulates rostro-caudal differentiation. Definitive MN-
specific transcription factors include, among others, HB9, ISL1 and LHX3 [74, 75]. 
In vitro neurogenesis has been reported by direct conversion of somatic cells or from 
ESCs/iPSCs [17, 38, 76]. Neural commitment can be achieved after neuroectoderm 
induction by RA or dual SMAD inhibition from iPSCs [27, 29, 77-82], and several 
neuronal subtypes have been successfully generated in vitro [83]. Patient-specific 
iPSCs can be prospectively differentiated into different neural cell types, which are 
expected to become a unique tool/strategy for disease modeling and future in vivo cell 
replacement therapies [38].   
III.1.4.SKELETAL MUSCLE TISSUE 
Muscle is a soft tissue formed during embryogenesis through a process known as 
myogenesis [84]. Three types of muscle are found in mammals, which vary with respect 
to function and anatomical location: skeletal muscle (SkM), smooth muscle and cardiac 
muscle. SkM refers to multiple bounded cells called muscle fibers or muscle cells. 
During myogenesis, SkM cells are formed through the fusion of developing myoblasts. 
Embryonic muscle progenitor cells express two master genes responsible for the 
survival and specification of the myogenic lineage, PAX3 and PAX7, and are 
maintained as a self-renewing proliferative population [85]. These muscle progenitors 
are quiescent and are held in reserve as resident satellite cells until needed for postnatal 
growth or repair. During embryogenesis or after muscle damage, satellite cells are 
activated to proliferate and differentiate to form new muscle cells [86]. The PAX7 
transcription factor is a bona fide marker for quiescent satellite cells, and upon 
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stimulation/activation, satellite cells express the myogenic determination factor MYF5, 
a PAX7 target, which is required for proliferation and further commitment into 
myoblasts [85, 87]. Along with MYF5, the myogenic regulatory factors MYOD and 
MYOGENIN, which are essential for SkM differentiation from myoblasts, are 
upregulated. Concommitanly, PAX7 is downregulated and myotubes (the mature SkM 
cell) present PAX7 inactivation and an upregulation of myotube-specific markers such 
α-actin, MHC and muscle creatine kinase (Figure 8) [88]. This terminal differentiation 
is accompanied by the absence of proliferation [87].   
Several studies have demonstrated the capacity of ESC/iPSCs to differentiate into SkM 
[89-93]. The most efficient methodology described thus far is the introduction of an 
inducible transgene, such as PAX7 or MYOD, which drives cells towards the myogenic 
lineage, acquiring engraftment and regenerative potential in vivo. Nevertheless, a major 
challenge for cell therapy or drug screening is to scale up the differentiation process 
such that it renders a large enough supply of homogeneous SkM cells for downstream 
application [93, 94].  
FIGURE 8: Representation of SkM differentiation and maturation.  
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III.2.METABOLISM 
Metabolism can be considered a homeostatic process by which living organisms 
produce a well-synchronized network of chemical/enzymatic reactions aimed at 
modifying cellular structures and basic/elemental metabolites to meet physiological 
demands. 
Metabolism can be divided into two phases: 
1. Anabolism: set of metabolic pathways through which complex functional 
molecules are built from simple precursors. These reactions require chemical 
energy, which is supplied as ATP. Anabolic processes usually promote cell 
growth and differentiation.  
2. Catabolism: set of metabolic pathways that break down large molecules (e.g., 
polysaccharides, lipids, nucleic acids and proteins) into smaller units (e.g., 
monosaccharides, fatty acids, nucleotides and amino acids), which are either 
oxidized to release energy (ATP) or used in other anabolic reactions. 
Catabolism therefore provides the chemical energy required for anabolic cell 
growth and maintenance. Glucose is the main carbon source to produce ATP 
and its catabolism is tightly regulated by a balance between glycolysis, which 
occurs in the absence of oxygen, and OXPHOS, which is supplied with 
reducing power generated by the Krebs cycle in the mitochondrial matrix, 
leading to the consumption of oxygen.  
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III.2.2.GLYCOLYSIS 
Glycolysis is a catabolic pathway that converts glucose into pyruvate required for 
synthesis of ATP and NADH. Pyruvate can either be catabolized by the Krebs cycle to 
produce more ATP by OXPHOS, or converted to lactic acid by fermentation in the 
absence of ATP synthesis. Glycolysis is less efficient in terms of energy production (2 
ATPs are produced compared with 36 from OXPHOS); however, it produces energy at 
a faster rate and with a lower generation of ROS, which reduces oxidative damage, and 
also allows for ATP generation in the absence of oxygen. Cancer cells use glycolysis 
preferentially even in the presence of sufficient oxygen, a process termed the Warburg 
effect, to generate energy while preventing ROS generation and genome instability [95, 
96].  
During embryogenesis, the blastocyst switches metabolism from OXPHOS to 
glycolysis to prevent oxidative damage [97, 98]. Thus, ESCs derived from the inner 
cell mass as well as iPSCs maintain this glycolytic metabolism as a primary source of 
ATP [99]. In addition, early stage somatic cell reprogramming to iPSCs is accompanied 
by a switch from mainly OXPHOS to mainly glycolytic metabolism [99-103]. The 
predominantly glycolytic state allows the cell to produce energy linked to low levels of 
ROS and is maintained by the expression of HIF-1 and UCP2 [103, 104]. 
III.2.3.OXIDATIVE PHOSPHORYLATION 
OXPHOS is a mitochondrial process that uses oxidation of nutrients to generate a 
proton gradient between the mitochondrial matrix and the intermembrane space that is 
then used for multiple purposes including the import of proteins and calcium into the 
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mitochondrion, and for generating heat and ATP [105]. It is the main aerobic route to 
generate ATP from glucose and is more efficient than glycolysis. Electron donors 
(NADH + H+ and FADH2) produced by the Krebs cycle or by β-oxidation in the 
mitochondrion matrix are passed to electron acceptors such as oxygen in redox 
reactions to form water. These redox reactions are executed by four protein complexes 
embedded in the mitochondrial inner membrane that constitute the electron transport 
chain (ETC). The efficiency by which the electron transport is converted to ATP by 
OXPHOS is known as the coupling efficiency. This is determined by the efficiency 
through which protons are pumped out of the matrix by complexes I, III and IV and the 
efficiency by which proton flux through complex V is converted to ATP [105]. 
Mitochondrial OXPHOS consist of two subsystems, the ETC (from complex I to 
complex IV) and the ATP synthase (Complex V) (Figure 9): 
- Complex I (CI) or NADH-coenzyme Q oxidoreductase: is the largest and most 
robust electron acceptor and oxidizes NADH to NAD, transferring electrons 
to coenzyme Q10 (CoQ10), which is reduced. It is a proton pump formed by 46 
subunits and is the major ROS producer in the cell, which can damage the 
mitochondrial DNA (mtDNA) and cause aging-like degenerative changes and 
sporadic Parkinson disease [106-109]. 
- Complex II (CII) or succinate-Q oxidoreductase: is the second entry point to 
the ETC. CoQ10 is reduced by the electrons transferred from succinate or 
FADH2. This complex is unable to transfer protons into the intermembrane 
space. Succinate accumulation can be generated by mutations in CII, which 
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can increase ROS generation and related genomic instability provoking 
metabolic disease [110-112]. 
- Complex III (CIII) or coenzyme Q-cytochrome c oxidoreductase: is a dimer, 
with each monomer containing 11 protein subunits. The reaction catalyzed is 
the oxidation of CoQ10 and the reduction of the electron carrier cytochrome c, 
which shuttles electrons to complex IV and protons are pumped into the 
intermembrane space. Encephalomyopathy or Leber hereditary optic 
neuropathy provoked by superoxide overproduction can be caused by 
mutations in CIII [113-115].  
- Complex IV (CIV) or cytochrome c oxidase: is the final complex in the ETC. 
It contains 13 subunits and mediates electron transfer from cytochrome c to 
oxygen to form water, at the same time removing protons from the matrix and 
contributing to the proton gradient. CIV deficiencies are heterogenic disorders 
and range from myopathy to multisystemic disorders [116].   
- Complex V (CV) or ATP synthase: is the final enzyme of OXPHOS. This 
enzyme uses the energy stored in the proton gradient across the mitochondrial 
membrane to synthesize ATP from ADP and Pi. This phosphorylation reaction 
is in equilibrium, which can be shifted by altering the protonmotive force. In 
the absence of protonmotive force, ATP synthase hydrolyzes ATP. 
The function or textbook description of the ETC in the mitochondria cannot be fully 
explained by the classical fluid model [117] or the solid model, which proposes that the 
respirasome (CI, CIII and CIV) is the only functional mitochondrial ETC [118]. It is 
thought that both models coexist in a dynamic way. Complexes are organized into 
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independent supercomplexes [119], likely due to their dependence on physical 
interaction for functionality and to optimize the use of available substrates [120].  
III.2.4.REACTIVE OXYGEN SPECIES  
ROS are chemical species formed after the incomplete reduction of oxygen, and include 
peroxides, superoxides, hydroxyl radicals and singlet oxygen [121]. In a biological 
context, ROS are formed as natural byproducts of oxygen metabolism and play key 
roles as second messengers in cell signaling and homeostasis [108, 122-124]. ROS 
levels can increase after environmental stress, and can damage cellular structures by 
oxidation. ROS can be produced by exogenous insults (drugs, radiation) or 
endogenously from normal cellular metabolic processes. Mitochondria generate the 
FIGURE 9: Classical view of OXPHOS: Representation of the electron transport chain in 
the mitochondrial inner membrane. Complexes I and II transfer electrons from NADH and 
FADH2, respectively, to complex III via CoQ
10 
(Q). Complex III transfers electrons to 
complex IV via cytochrome c (Cyt c). Complex IV uses the electrons to reduce oxygen to 
water. Complex V uses the proton gradient force created by electron transfer across the inner 
mitochondrial membrane to synthesize ATP. 
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majority of endogenous ROS during OXPHOS [109, 125], which under physiological 
conditions is tightly regulated [126]. Dysfunction in the ETC can lead to a leakage of 
superoxide anion, which can subsequently be converted to other types of ROS including 
hydrogen peroxide. ROS can damage cellular proteins, lipids and nucleic acids [105], 
a phenomenon known as oxidative damage. If too much oxidative damage is present in 
mitochondria, the cell launches the apoptosis mechanism via the pro-apoptotic BCL-2 
family and/or cytochrome c pathways. Excessive production of ROS can cause 
deleterious effects in the organism, which is evident in the human degenerative diseases 
such as Parkinson or Alzheimer [127, 128]. Mitochondrial dysfunction is a source of 
ROS that can provoke oxidative damage and induce cellular senescence [129-131]. 
III.2.5.MITOCHONDRIAL METABOLISM 
The mitochondrion is a double membrane organelle found in all eukaryotic organisms, 
although some cells such as erythrocytes lack mitochondria and use glycolysis to 
synthesize ATP. The mitochondrial genome is a double-stranded circular molecule of 
16659 base pairs and encodes 13 polypeptides involved in OXPHOS [132, 133]. 
Mitochondria vary considerably in terms of size and structure due to continuous cycles 
of fission and fusion, termed mitochondrial dynamics, which regulates mitochondrial 
morphology and function [134]. Mitochondrial fusion and fission not only merges the 
mitochondrial inner and outer membranes, but also mixes mitochondrial matrices and 
redistributes mtDNA. Loss of mitochondrial fusion causes a normally connected 
network to fragment into multiple small mitochondria due to fission [134, 135]. Besides 
their traditional role as the cellular powerhouse, mitochondria are involved in cellular 
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signaling and differentiation as well as cell death, cell growth and proliferation [105, 
136, 137].  
Mutations in either mtDNA genes or in nuclear genes that encode mitochondrial 
polypeptides required for aerobic ATP production cause a broad and often devastating 
spectrum of human mitochondrial diseases, which can affect any organ in the body. 
Tissues with high energetic demand like the CNS or SkM are those mainly affected in 
mitochondrial diseases [138]. In addition, there is a wide degree of clinical 
heterogeneity in mitochondrial disease. Some of this heterogeneity can be explained by 
the fact that cells can contain a variable percentage of mutated mtDNA, the presence of 
more than one type of mtDNA in the cell is named heteroplasmy and is an important 
factor of disease severity. Mitochondrial diseases are not only related to the ETC and 
metabolic disorders, but they can also contribute to cancer and neurodegenerative 
diseases, such as Parkinson, Alzheimer or Huntington disease [138-142]. 
III.2.6.COENZYME Q10  
CoQ10 was discovered by Festenstein and Crane in the mid-1950s [143, 144] as a redox-
active lipophilic molecule present in all eukaryotic species. It is composed of a quinone 
ring, which provides redox function, connected to a polyisoprenoid side chain of 
variable length, which anchors it to cellular membranes (Figure 10A) (10 in humans, 
9 in mice and 6 in yeast) [145, 146]. CoQ10 is found in the plasma membrane and several 
endomembrane systems. CoQ10 has an essential role in the inner mitochondrial 
membrane because of its function in the ETC, which is to shuttle electrons from CI and 
CII to CIII (Figure 9). CoQ10 also cooperates in the oxidation of fatty acids, pyrimidine 
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biosynthesis [147], and opening of the permeability transition pore [148]. It is also one 
of the main cellular antioxidants [149] and an essential cofactor of uncoupling proteins 
[146, 150, 151].  
FIGURE 10: CoQ
10
 structure and biosynthesis. A) Structure of the oxidized (ubiquinone) and 
reduced (ubiquinol) form of CoQ
10
.
 
B) Schematic representation of CoQ
10
 biosynthesis in 
mammalian cells. 4-hydroxybenzoate (4HB) is derived from tyrosine. COQ4 has a central 
structural role in the multienzymatic complex. Several enzymatic steps are still unclear and 
are represented by question marks. Modified from [145]. 
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CoQ10 biosynthesis is a complex pathway that remains incompletely understood. 
Proteins encoded by different COQ genes are involved in CoQ10 biosynthesis between 
the cell cytoplasm and mitochondria by multienzymatic complex assembly, the exact 
composition and organization of which is not completely clear (Figure 10B) [145, 152]. 
The precursor of the quinone ring is 4-hydrozybenzoate, which is derived from tyrosine 
through a still uncharacterized set of reactions, while the isoprenoid tail is synthesized 
through the mevalonate pathway by PDSS1/PDSS2 to be condensed to the quinone ring 
by COQ2. COQ3, COQ5, COQ6 and COQ7 proteins are involved in methylation and 
decarboxylation, hydroxylation (COQ6 and COQ7), respectively. FDX1L and FDXR 
provide electrons for COQ6 activity. ADCK3 and ADCK4 are kinases essential for 
phosphorylation of COQ3, COQ5 and COQ7. COQ9 is a lipid-binding protein 
necessary to stabilize COQ7. COQ10A/B is most probably a chaperone required for 
correct localization of CoQ10 within the mitochondrial membrane. The function of 
COQ4 is still unknown; there is evidence however that is required for the assembly and 
stability of the multienzymatic complex [145, 153, 154].  
III.2.6.1.COENZYME Q10 DEFICIENCY 
CoQ10 has been implicated in many common disorders that present with increased 
oxidative stress, such as neurodegenerative diseases, cancer, diabetes, aging and 
Alzheimer, among others. However, a specific group of rare conditions has been 
characterized by a deficiency in CoQ10 [155]. CoQ10 deficiency was described in 
patients for the first time in 1989 [156], and was associated with a diverse range of 
clinical phenotypes. The hallmark of this disease is a decrease in the concentration of 
CoQ10 in muscle and/or fibroblasts below 50% of standard values. CoQ10 deficiency is 
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considered a rare and heterogeneous group of metabolic/mitochondrial disorders 
(OMIM #607426) that are frequently diagnosed during childhood [157].  
Mutations in COQ genes cause primary CoQ10 deficiency, whereas secondary CoQ10 
deficiency is caused by mutations in genes not related to the CoQ10 biosynthetic 
pathway [154, 157], such as APTX, ETFDH, BRAF1, as well as many mtDNA defects. 
However, not all mutations in APTX or ETFDH lead to CoQ10 deficiency, and thus it is 
unclear why some patients develop the deficiency and other not. Moreover, in all these 
scenarios CoQ10 deficiency is always a secondary insult and it is not the critical event 
of the disease [154, 157]. Since the first described case of primary CoQ10 deficiency 
[156], several mutations in genes involved in CoQ10 biosynthesis have been reported, 
such as COQ2 [158-162], COQ6 [163], ADCK3 [160, 164, 165], ADCK4 [166], COQ9 
[160, 167], PDSS1 [168], PDSS2 [169] and COQ7 [170], and all result in a reduction 
in CoQ10 levels. These conditions are very rare, and the clinical manifestations have 
been clustered into five main phenotypes: encephalomyopathy, cerebellar ataxia, severe 
infantile multisystem disorder, nephropathy and isolated myopathy [145, 153, 156-158, 
171-183].  
III.2.6.2.COQ4 MUTATIONS 
The COQ4 gene, which contains seven exons spanning approximately 12 kb [184], 
encodes a component of the CoQ10 biosynthesis pathway. It has been previously 
suggested that COQ4 has an essential structural role in the biosynthesis of CoQ10 [152, 
154, 184]. In addition, several biallelic missense mutations in COQ4 as well as COQ4 
haploinsufficiency cause a broad spectrum of mitochondrial disorders affecting mainly 
the CNS and SkM, such as encephalomyopathy, cerebellar atrophy, hypotonia, 
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respiratory distress and neurological deterioration, among others, which are associated 
with CoQ10 deficiency with early fatal outcome [175, 176, 178]. The pathogenic role 
of some identified mutations has been experimentally validated in a recombinant yeast 
model: null-COQ4 yeast can be effectively complemented by human COQ4. Moreover, 
yeast have been transformed with mutated variants of human COQ4 to functionally test 
the effect of some mutations for CoQ10 biosynthesis [175, 184]. 
III.3.DISEASE MODELING  
Human diseases are generally studied once the full genetic, epigenetic and metabolic 
events  are already in place and, therefore, the mechanisms of disease pathophysiology 
are not amenable to analysis with primary patient samples [9]. In this sense, the advent 
of iPSC technology has revolutionized biomedical research, opening up unprecedented 
avenues in developmental biology and also drug screening and disease modeling, which 
are some of the most promising applications for regenerative medicine. While iPSCs 
are widely being used in disease modeling, they are envisioned to become a unique tool 
for disease-specific drug screening, and possibly, patient-specific cell replacement 
approaches [24]. The full potential of iPSC technology relies on the ability to 
modify/correct specific genome sequences, with the ultimate goal of personalized 
therapy. Importantly, genome editing techniques such as CRISPR/Cas9 system offer a 
new perspective on genome editing, which together with iPSCs may provide a unique 
in vitro model to explore the developmental impact of specific mutations [1, 9, 20, 24].  
Fibroblasts are the main source of iPSCs, although other sources of iPSCs have been 
reported, including CB cells and mature B cells, etc [2, 15, 20, 23, 24]. iPSCs may be 
differentiated in vitro into a variety of cell lineages. Over the last years, many attempts 
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have been made to optimize various differentiation protocols to achieve a homogeneous 
and functional cell population [25-29, 89, 93, 185]. The unlimited source of 
differentiated cells from patient-derived iPSCs would allow the investigation of the 
initiation and development of diseases in vitro. For example, patient-derived iPSCs 
differentiated in vitro and in experimental models in vivo can reproduce the patient’s 
phenotype in some neural diseases, such as retinitis pigmentosa [186], frontotemporal 
dementia [187] or Rett syndrome [188, 189]. Additionally, iPSC-derived neurons from 
Parkinson patients manifested autophagy dysfunction [190] or oxidative damage [127]. 
A comprehensive study using monozygotic twins demonstrated that iPSC-derived 
neurons are more affected in the diseased twin than in the healthy twin, revealing the 
significance of this model [191]. Moreover, non-neural diseases are also recapitulated 
with in vitro iPSC differentiation, such as Fanconi anemia, progeria and familial 
cancers, among others [24, 192-195].  
As stated earlier, CoQ10 deficiency is a heterogeneous disease that leads to 
encephalomyopathies because the disruption in energy metabolism affects tissues with 
high-energy demands such as the CNS and SkM. Since many COQ genes have been 
implicated in primary CoQ10 deficiency, the molecular diagnosis and clinical 
heterogeneity remains challenging. To date, there is no clear genotype-phenotype 
association [145, 153], and the only current treatment is CoQ10 supplementation, which 
is usually variable in the patients and is a demanding treatment [145, 177]. It is therefore 
an ideal candidate disease to be reproduced with iPSCs to gain insight into the 
developmental impact of COQ4 mutations in mitochondrial dynamics, CoQ10 
biosynthesis and also in the observed neuronal and SkM phenotypes.  
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III.4.CRISPR/CAS9: A UNIQUE AN 
UNPRECEDENTED TOOL FOR GENE EDITING 
CRISPR/Cas9 systems are genetic hallmarks of adaptive immunity in bacteria and 
archea that have evolved to target and eliminate invading genetic elements such as 
viruses and plasmids [196]. During last few years, the CRISPR/Cas9 system has 
become a powerful tool for basic and applied science. Among the increasing numbers 
of papers published in the field, one of the latest studies has utilized this system as a 
tool to track RNAs in living cells, exploiting the inactivated-nuclease activity of Cas9 
to bind in the cell to RNA [197], thus expanding the utility of such a methodology.  
CRISPR/Cas9 specification is based on RNA-DNA recognition. Several delivery 
systems, such as lentiviral transduction, electroporation and transfection, have been 
employed to introduce the small guide RNAs (sgRNA) and the Cas9 protein into cells. 
Cas9 is a nuclease that is guided by ~20 nucleotides sgRNAs towards a specific DNA 
cleavage site, which is three nucleotides upstream of the protospacer-adjacent motif 
(PAM) (5’-NGG-3’), introducing a double-strand break (DSB) [198, 199]. The DSBs 
generated by CRISPR are preferentially repaired by non-homologous end joining 
(NHEJ), which is an error-prone process and thus useful to introduce insertions and 
deletions into mammalian cells. In addition, DSBs are resolved at a lower frequency by 
homology direct repair (HDR) and therefore can be used to modify endogenous loci, 
such as generating point mutations, inserting genes or DNA editing. HDR can be 
influenced by the presence of an exogenous template, which can either be in a double-
stranded DNA with homology arms flanking the insertion sequence, or single-stranded 
DNA (Figure 11). Generation of DSBs in off-target locations can occur because 
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gRNAs bind to a nonspecific DNA sequences similar to the target site. To increase the 
specificity of Cas9-mediated genome editing, a Cas9 has been developed with nickase 
activity to enhance HDR over NHEJ [200, 201]. The CRISPR/Cas9 system has been 
used recently to repair a wide range of monogenic diseases both in human and mouse 
models [202-206].   
FIGURE 11: Representative cartoon of CRISPR/Cas9 system and dsDNA repair after the 
formation of a double-strand brake (DSB). NUC: DNA nuclease Cas9. NHEJ: non-homologous 
end joining. HDR: homology direct repair. PAM: protospacer-adjacent motif   Modified from 
Advanced analytical (http://www.aati-us.com). 
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III.5.ARTICLE I:  
Concise review: Generation of neurons from somatic cells of healthy 
individuals and neurological patients through induced pluripotency or direct 
conversion. 
Velasco I, Salazar P, Giorgetti A, Ramos-Mejía V, Castaño J, Romero-Moya 
D, Menendez P. 
Stem Cells. 2014; 32(11):2811-7.  
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1. Part I: 
- Hypothesis: Mitochondrial activity and/or mitochondrial mass segregate stem 
versus progenitor function in CB-derived CD34+ (CB-CD34+) cells. 
- Objectives: 
a. To examine the correlation between mitochondrial activity and 
mitochondrial mass in CB-CD34+ cells. 
b. To assess in vitro the mitochondrial energetic balance in CB-CD34+ 
cells. 
c. To assess in vivo hematopoietic stem/progenitor cell function in CB-
CD34+ cells contingent on their mitochondrial contribution. 
2. Part II: 
- Hypothesis: Patient-specific iPSCs carrying a mutation in COQ4 could be 
useful to determine its developmental impact on CoQ10 metabolism and also 
on the phenotypes observed in the patient.  
- Objectives: 
a. To generate and characterize human iPSCs from CoQ10-deficient 
fibroblasts.  
b. To edit the COQ4 mutation using CRISPR/Cas9 technology in 
CoQ10-deficient iPSCs.  
c. To characterize the metabolic profile of patient-derived iPSCs and 
iPSC-derived SkM cells. 
d. To assess the developmental impact of the COQ4 mutant in iPSCs 
differentiated into neural and SkM cells. 
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V.1.SUMMARY OF THE RESULTS 
A brief summary of the main results achieved during the development of this work is 
described below. All figures and extended results are available in the published papers 
included in this thesis. 
CB-CD34+ hematopoietic cells with low mitochondrial mass are enriched in 
hematopoietic repopulating stem cells (Article II). 
1. FACS sorting of CD34+ cells based on mitochondrial mass. 
A strong correlation was found between mitochondrial mass and MMP in CB-
CD34+cells i.e., the greater the mitochondrial content, the higher the MMP. 
CD34+ cells were sorted according to their mitochondrial mass into CD34+ 
MitoHigh and CD34+ MitoLow populations. Both ATP levels and the expression 
of the mitochondrial-specific ND1 and COX2 genes were higher in sorted 
CD34+ MitoHigh cells than in equivalent CD34+ MitoLow cells.  
2. Stem versus progenitor cell function of sorted CD34+ cells. 
We used clonogenic colony-forming units (CFU) assays as an in vitro read-
out of HPC function, and BM xenotransplantation assays into NSG (NOD.Cg-
Prkdcscid Il2rgtm1WjI/SzJ) mice as an in vivo read-out of HSC function. CD34+ 
MitoHigh cells displayed higher clonogenic activity both in primary and 
secondary CFU assays than CD34+ MitoLow cells. However, the level of 
engraftment was higher in mice transplanted with CD34+ MitoLow cells than in 
those transplanted with CD34+ MitoHigh cells irrespective of the tissue 
analyzed, and was more significant in the injected BM. We also analyzed the 
proportion of CD34+CD38- (HSC) cells within the CD34+ MitoHigh and MitoLow 
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fraction and found that the CD34+ MitoLow fraction contained a 6-fold higher 
number of HSC than the CD34+ MitoHigh fraction. Together, these data suggest 
that the CD34+ MitoHigh fraction is enriched in HPC whereas the CD34+ 
MitoLow fraction is enriched in HSC. 
3. In vitro homeostasis of MitoHigh and MitoLow CD34+ cells. 
Expansion of CD34+ cells in vitro while retaining their stem/progenitor 
properties remains challenging [46, 49]. We analyzed the in vitro 
differentiation kinetics of CD34+ MitoHigh and MitoLow cells by tracing the loss 
of the CD34 antigen. CD34 expression declined progressively during 
differentiation in both populations; however, the decline was less pronounced 
in CD34+ MitoLow cells. Moreover, whereas the expansion of CD34+ MitoHigh 
and MitoLow cells was similar during the first few days of differentiation, the 
number of CD34+ MitoLow cells was significantly higher after 10–15 days of 
culture. Finally, the complete differentiation of CD34+ MitoLow cultures and 
their expansion from day 15 was accompanied by mitochondrial adaptation, 
as demonstrated by an increase in ATP production and expression of the 
mitochondrial genes ND1 and COX2. These data suggest that the 
mitochondrial response underlies the high proliferative capacity of the CD34+ 
MitoLow-differentiated derivatives. 
Genetic rescue of mitochondrial and SkM impairment in an iPSC model of CoQ10 
deficiency (Article III & IV). 
1. A COQ4 mutation causes a mitochondrial disorder associated with CoQ10 
deficiency. 
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A 4-year-old girl was diagnosed in our Institution with minor mental 
retardation and lethal rhabdomyolysis. Genetic analysis identified a 
heterozygous point mutation in the COQ4 gene (c.483G>C; E161D). A 
comparative analysis of the patient´s fibroblasts (CQ4-F) and control 
fibroblasts (Ctrl-F) revealed that the concentration and biosynthesis of CoQ10 
was 75% and 87% lower, respectively, in CQ4-F than in Ctrl-F. In line with 
its role in the ETC, the reduction in CoQ10 in CQ4-F was reflected in the 
functional reduction in the activity of CI+III and CII+III of 41% and 64%, 
respectively. Moreover, cellular proliferation was considerably lower in CQ4-
F than in Ctrl-F and the proportion of cycling cells was decreased in CQ4-F, 
which was accompanied by a 17-fold increase in senescence. Finally, 
histological analysis of SkM from the patient revealed extensive damage 
associated with rhabdomyolysis. 
2. Generation and characterization of patient-specific CQ4-iPSCs. 
CQ4-F were reprogrammed into iPSCs in an attempt to model CoQ10 
deficiency by exploring the functional impact of the COQ4 mutation on 
neuronal and muscle cell fate. iPSC colonies emerged 16–18 days after OSKM 
transduction and were picked and expanded for further characterization. After 
8–10 passages, iPSC lines were OSKM transgene independent, expressed the 
pluripotency-associated markers (OCT4, SOX2, REX1, NANOG, TRA-1-60, 
SSEA4), and were genetically stable. As a final test of pluripotency, iPSCs 
were able to form teratomas in immunodeficient mice.  
3. iPSC gene editing by CRISPR/Cas9. 
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Because the differentiation capacity among iPSCs lines is influenced by 
epi/genetic variability [36, 37], the best method to identify genotype-
phenotype associations is to use isogenic pairs of iPSCs. We therefore used 
the CRISPR/Cas9 system to edit (and correct) the COQ4 mutation in iPSCs 
(CQ4ed-iPSCs). CQ4-iPSCs were co-transfected with Cas9-GFP vector and 
ssDNA. Two days later, GFP+ cells were FACS-sorted as single cells. 
Individual established clones were analyzed and a homozygous edited clone 
was observed and confirmed by sequencing. Importantly, CQ4ed-iPSCs 
remained pluripotent. 
4. COQ4 genome editing reverses metabolic/mitochondrial dysfunction. 
CoQ10 is involved in the ETC and low levels of CoQ10 in fibroblasts or muscle 
are linked to CoQ10 deficiency [146, 150, 157]. We found that CoQ10 
concentration and biosynthesis was significantly lower (36% and 61%, 
respectively) in CQ4-iPSCs than in Ctrl-iPSCs. Interestingly, full restoration 
both of CoQ10 concentration and biosynthesis was found in CQ4ed-iPSCs. 
Next, we evaluated OXPHOS and glycolysis by ATP production, basal live-
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). 
To produce the same amount of ATP, ECAR and OCR rates were 2-fold higher 
in CQ4-iPSCs than in CQ4ed-iPSCs, suggesting a respiration dysfunction as 
confirmed by a 2-fold increase in proton leak. Together, these results suggest 
that CQ4-iPSCs maintain the CoQ10 deficiency and metabolic dysfunction, 
however the correction in CQ4ed-iPSCs ameliorates these deficiencies. 
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5. The COQ4 mutation does not impair iPSC differentiation into 
dopaminergic or motor neurons.  
The majority of CoQ10-deficient patients present neurological symptoms [172, 
174]; however, the patient described here presented only minor mental 
retardation. To study the potential developmental impact of the COQ4 
mutation in human neurogenesis Ctrl-, CQ4- and CQ4ed-iPSCs were 
differentiated into DAns [27] and MNs [29]. No differences were found 
between Ctrl- and CQ4-iPSCs irrespective of the differentiation protocol. We 
evaluated the differentiation capacity to neural progenitors (SOX2+NESTIN+) 
and immature neurons (TUJ1+) at early time points. Furthermore, we assessed 
the differentiation potential of the neural progenitors and neural maturation by 
TH+ (DAn) or HB9+/ISL1+ (MN) at later time points. CQ4ed-iPSCs obtained 
similar percentages of differentiation to those of CQ4-iPSCs. We then carried 
out functional analysis to confirm these results. HPLC determination of 
dopamine release revealed similar levels of dopamine in Ctrl- and CQ4-iPSCs-
derived neurons. Whole-cell patch clamp recording of MNs indicated that 
CQ4-iPSC-derived MNs were electrophysiologically active. Together, these 
data reveal that the c.483 G>C mutation in COQ4 does not impact 
dopaminergic or motor neurogenesis from iPSCs, faithfully recapitulating the 
patient’s phenotype.  
6. A COQ4 mutation recapitulates CoQ10-deficiency-associated SkM 
functional and metabolic defects. 
Muscle impairment is common in CoQ10-deficient patients [154]. To study the 
developmental and metabolic impact of the COQ4 mutation in skeletal 
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myogenesis, Ctrl-, CQ4- and CQ4ed-iPSCs were differentiated into SkM [89]. 
Transgenic iPSCs lines carrying a PAX7-GFP-inducible lentivirus vector were 
generated. Although the cell cycle profile and levels of apoptosis were very 
similar between Ctrl- and CQ4-PAX7+ myogenic progenitors, the number of 
senescent CQ4-PAX+ cells was 2-fold higher, a phenotype that was corrected 
in CQ4ed-PAX7+ myogenic progenitors. The senescence observed in CQ4-
PAX7+ cells might be explained by their increased ROS production, leading 
to a 1-log reduction in cell expansion. Again, this functional deficiency was 
corrected in CQ4ed-PAX7+ cells. PAX7+ myogenic progenitors were further 
differentiated into muscle cells. A significant reduction in the generation of 
fully differentiated MYH+ cells was noted for CQ4-PAX7+ myogenic 
progenitors, and this was paralleled by a decrease in creatine kinase activity. 
Moreover, gene expression analysis of specific myogenic markers (MYF5, 
MGN and MYH3) showed that their kinetics were deregulated in CQ4-PAX7+ 
when compared with Ctrl-PAX7+ differentiating muscle cells. Moreover, 
mitochondrial dynamics (circularity, form factor and aspect ratio) and ETC 
activity (CI+III) were also reduced in complexity and activity, respectively, in 
CQ4-PAX7 differentiated cells relative to Ctrl- and CQ4ed-PAX7+ 
differentiated cells. Collectively, these results establish the utility of an iPSC-
based disease model that partially reproduces the disease phenotype. 
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ABSTRACT 
Coenzyme Q10 (CoQ10) plays a crucial role in mitochondria as an electron carrier within the 
mitochondrial respiratory chain (MRC), and is an essential antioxidant. Mutations in genes 
responsible for CoQ10 biosynthesis (COQ genes) cause primary CoQ10 deficiency, a rare and 
heterogeneous mitochondrial disorder with no clear genotype-phenotype association, mainly 
affecting tissues with high-energy demand including brain and skeletal muscle (SkM). Here, we 
report a 4-year old girl diagnosed with minor mental retardation and lethal rhabdomyolysis 
harboring a heterozygous mutation (c.483G>C (E161D)) in COQ4. The patient’s fibroblasts 
showed a decrease in [CoQ10], CoQ10 biosynthesis and MRC activity affecting complexes I/II+III. 
Bona fide induced pluripotent stem cell (iPSCs) lines carrying the COQ4 mutation (CQ4-iPSCs) 
were generated, characterized and genetically edited using CRISPR-Cas9 (CQ4ed-iPSCs). 
Extensive differentiation and metabolic assays of control-iPSCs, CQ4-iPSCs and CQ4ed-iPSCs 
demonstrated a genotype association, reproducing the disease phenotype. The COQ4 mutation 
in iPSC was associated with CoQ10 deficiency, metabolic dysfunction and impaired differentiation 
into SkM; remarkably, iPSC differentiation in dopaminergic or motor neurons was unaffected. 
This study offers an unprecedented iPSC model recapitulating CoQ10 deficiency-associated 
functional and metabolic phenotypes caused by COQ4 mutation.  
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INTRODUCTION 
Coenzyme Q10 (CoQ10) is a lipid-soluble molecule ubiquitous to cellular membranes that has 
essential functions in many cellular processes including energy/ATP production, where it shuttles 
electrons from complex I and II to complex III in the mitochondrial respiratory chain (MRC). CoQ10 
also participates in beta-oxidation of fatty acids, pyrimidine biosynthesis, and it is one of the main 
cellular antioxidants[1, 2]. Proteins encoded by different COQ genes are involved in the pathway 
of CoQ10 biosynthesis between the cytoplasm and mitochondria by functioning as a 
multienzymatic complex[3]. Several mutations in genes involved in CoQ10 biosynthesis, such as 
COQ2[4-7], COQ6[8], ADCK3[7, 9, 10], ADCK4[11], COQ9[7, 12], PDSS1[13], PDSS2[7, 14] 
and COQ7[15], have been described, and all result in a reduction in CoQ10 levels. CoQ10 levels 
below 50% of standard values are indicative of CoQ10 deficiency, which is a rare and 
heterogeneous group of metabolic/mitochondrial disorders (OMIM#607426)[16], frequently 
diagnosed during childhood. CoQ10 deficiency associates with multiple clinical phenotypes 
including kidney failure[13] and neurological and neuromuscular diseases, such as mental 
retardation, seizures, and ataxias, affecting tissues with high energetic demand such as muscle 
and neurons[16-18].  
It has been suggested that COQ4 has an essential structural and functional role for the 
biosynthesis of CoQ10[19-21]. Indeed, COQ4 mutations as well as COQ4 haploinsufficiency 
cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency[22-24]. We 
identified CoQ10 deficiency in a 4-year-old girl with a heterozygous missense mutation (c.483 
G>C) in COQ4. This patient did not display (or very mild) symptoms of impaired 
neurodevelopment or neurodegeneration, but presented severe metabolic/mitochondrial defects 
accompanied with lethal rhabdomyolysis. CoQ10 deficiency is a heterogeneous disease, and a 
major obstacle to study this disorder is the lack of association between the genotype and 
phenotype[3, 25], which partly explains the highly variable patient response to CoQ10 
supplementation[3, 26, 27]. Interestingly, the COQ4 E161D variant found in this patient has also 
been reported to have a minor allele frequency (<0.5%) in the population, so that whether it 
represents a driver pathogenic mutation or a cooperating hit in the underlying pathogenesis of 
more diseases is unknown. 
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Human disease is generally studied once all (epi)genetic/metabolic insults have already occurred 
and, therefore, the mechanisms by which disease-specific mutations impair normal homeostasis 
are not amenable to analysis with patient samples. In this regard, induced pluripotent stem cells 
(iPSC) together with genome editing strategies for correction of disease-causing mutations are 
powerful tools for modeling different aspects of human disease that cannot otherwise be 
addressed by patient sample analyses or animal models[28, 29]. iPSC are routinely generated 
from different cell types derived from both healthy donors and patients[30-33], thus providing a 
unique in vitro platform to explore the developmental impact of disease-specific genetic 
aberrations on human stem cell fate, especially in early-onset or developmental diseases[28].  
Here, we have generated and CRISPR/Cas9-edited iPSC lines from a patient carrying a COQ4 
missense mutation to analyze its developmental and metabolic/mitochondrial impact. 
Developmental and metabolic assays reproduce the disease phenotype. In line with the patient`s 
symptoms, the COQ4 mutation was associated with CoQ10 deficiency, metabolic dysfunction and 
impaired differentiation into skeletal muscle (SkM). Notably, the COQ4 c.483 G>C (E161D) did 
not impair iPSC differentiation into neural tissues. This study offers a unique human iPSC model 
recapitulating CoQ10 deficiency-associated functional and metabolic phenotypes caused by 
COQ4 mutation.   
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MATERIAL AND METHODS 
iPSC generation, maintenance and characterization 
Fibroblasts were maintained in low glucose DMEM supplemented with 20% FBS and 1% 
penicillin/streptomycin (P/S). Control iPSCs (Ctrl-iPSC) and COQ4-mutated iPSC (CQ4-iPSC) 
were generated using the CytoTune®-iPS Sendai Reprogramming Kit (Life Technologies) (Fig 
2A). iPSC clones were fully characterized and maintained undifferentiated on irradiated mouse 
embryonic fibroblasts (iMEF) in hESC media (KO-DMEM supplemented with 20% KO Serum 
Replacement, 1% GlutaMAX, 1% P/S, 1% NEAA and 0.1 mM β-mercaptoethanol (all from Life 
Technologies)) and 10 ng/ml basic fibroblast growth factor (bFGF; Miltenyi), or on Matrigel (BD) 
with MEF-conditioned media (MEF-CM). iPSCs were passaged when confluent with 0.1% 
collagenase IV/dispase or 0.05% trypsin. 
The COQ4 mutation was characterized in both patient fibroblasts and iPSC using PCR and 
Sanger sequencing. Primary dermal fibroblasts (CQ4-F) were obtained from the patient in 
accordance with procedures approved by the Clinic Hospital of Barcelona. Informed consent was 
obtained in accordance with the Declaration of Helsinki. Age-matched control human dermal 
fibroblasts (Ctrl-F) were obtained from Tebu-Bio.  
Established iPSC were fully characterized as previously described [31, 34]. SeV elimination was 
determined by qRT-PCR. Expression of pluripotency markers was performed by immunostaining 
(alkaline phosphatase, OCT4, NANOG, SSEA4, TRA-1-60) and qRT-PCR (OCT-4, NANOG, 
SOX2, REX1, CRIPTO and DNMT3β) using the primers and antibodies previously described 
(Table S1 and S2). G-banding karyotype was performed as previously described [35]. For 
teratoma assays, the different iPSC clones were collected through enzymatic dissociation using 
collagenase IV, and 2 million cells were re-suspended and injected with 250 µl DMEM and 50ul 
Matrigel subcutaneously in the back of the NSG mice [36]. Animal experimentation was approved 
by the Animal Care Committee of the University of Barcelona. Tumors generally developed within 
6-8 weeks. Animals were sacrificed for teratoma dissection. After sectioning, the presence of 
cells from the three germ layer was assessed following Hematoxylin & Eosin staining [36]. 
Bisulfite pyrosequencing of OCT4 and NANOG promoters was done as described [31]. Briefly, 
bisulfite modification of genomic DNA was performed with the EZ DNA Methylation-Gold kit 
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(Zymo Research) following the manufacturer's instructions. The set of primers for PCR 
amplification and sequencing of NANOG and OCT4 were designed using the software PyroMark 
Assay Design (Table S1). Primer sequences were designed to hybridize with CpG-free sites to 
ensure methylation-independent amplification. PCR was performed with primers biotinylated to 
convert the PCR product to single-stranded DNA templates, using the Vacuum Prep Tool. After 
PCR amplification, pyrosequencing reactions and methylation quantification were performed 
using PyroMark Q24 reagents, equipment and software (Qiagen), according to manufacturer’s 
instructions. 
CRISPR/Cas9 gene editing 
For CRIPSR-Cas9 gene editing, undifferentiated CQ4-iPSC were treated with 10 µM ROCK 
inhibitor (Y27632) for 24 hours and then 2×105 cells were plated on Matrigel-coated 12-well 
plates. Cells were transfected with Lipofectamine 3000 (Life Technologies) and 5 µg of 
pSpCas9(BB)-2A-GFP (PX458) (Addgene plasmid # 48138), allowing the expression of both the 
guide RNA and the Cas9-GFP, together with 10 nM of antisense ssDNA donor. At 3 days post-
transfection, cells were GFP-sorted and plated as single cells on Matrigel-coated 48-well plates. 
The CRISPR Design Tool (http://tools.genome-engineering.org) was used for guide RNA design. 
The site-specific cleavage efficiency of up to 4 guide RNAs was tested in 293T cells using the 
T7 surveyor assay [37]. The most efficient guide RNA (~25%) was used. Predicted off-targets 
were identified using CRISPR Design Tool and analyzed in COQ4-edited iPSC (CQ4ed-iPSC) by 
Sanger sequencing.  
Dopaminergic differentiation 
Six different clones of iPSC were differentiated into dopaminergic (DA) neurons using the 
protocol for midbrain DA neuron induction described by Kriks et al.[38]. Briefly, iPSC were 
maintained in hESC media to day 5 and were then gradually adapted (25%, 50%, 75%, every 2 
days) to NIM medium (DMEM/F12, 1% N2 supplement, 2 µg/ml heparin, 1% NEAA, 1% 
GlutaMax and 1% P/S). From day 11, iPSC were grown in Neurobasal media (Neurobasal, 1% 
B27, 1% GlutaMax and 1% P/S). Media were supplemented with SB-431542 (10 µM; d0-d5; 
Sigma), LDN193189 (100 nM; d0-d11; Miltenyi), CHIR99021 (3 µM; d3-d13; Miltenyi), FGF8 
(100 ng/ml; d1-d7; Miltenyi), purmorphamine (2 µM; d1-d7; Stemgent), SAG (1 µM; d1-d7; 
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Tocris), BDNF (20  ng/ml; from d11; Miltenyi), GDNF (20 ng/ml; from d11; Miltenyi), DAPT (10 
µM; from d11; Tocris), db-cAMP (500 µM; from d11; Sigma), TGFβ3 (1 ng/ml; from d11; Miltenyi) 
and ascorbic acid  (AA, 200 µM; from d11; Sigma) (Fig 4A). On day 20, cells were dissociated 
using Accutase (Merck) and replated at 3 × 105 cells/cm2 on dishes pre-coated with polyornithine 
(15 µg/ml), laminin (1 µg/ml) and fibronectin (5 µg/ml) until analysis. Quantification of neural 
precursors and neurons was assessed by confocal microscopy/flow cytometry using anti-
NESTIN, anti-SOX2, anti-TUJ1, anti-TH and anti-NCAM antibodies, and qRT-PCR. Antibodies 
and primers used are detailed in Table S1 and S2.  
Motor neuron differentiation 
Six different clones of iPSC were differentiated into motor neurons (MN) using the protocol 
described by Amoroso et al.[39]. Briefly, iPSC were grown on iMEF, and embryoid bodies (EB) 
were generated by first treating cells with 0.1% collagenase IV/0.1% dispase during 60 minutes, 
followed by washing with KO-DMEM and replating into low-attachment plates in hESC media. 
Three days later, the medium was changed to NIM media until day 17, and then to Neurobasal 
media. Media were supplemented with Y27632 (10 µM; d0-d3; Sigma), SB-431542 (10 µM; d0-
d7; Sigma), LDN193189 (200 nM; d0-d7; Miltenyi), all-trans retinoic acid (RA, 1 µM; from d5; 
Sigma), AA  (2 µM; from d5; Sigma), BDFN (10 ng/ml; from d5; Miltenyi), purmorphamine (1 µM; 
from d7; Stemgent), SAG (1 µM; from d7; Tocris), GDNF (10 ng/ml; from d17; Miltenyi), CNTF 
(10 ng/ml; from d17; Miltenyi), and IGF-1 (10 ng/ml; from d17; Miltenyi) (Fig 5A). To analyze MN 
differentiation, EBs were dissociated into single cells using collagenase B for 2 hours and 
Dissociation Buffer for 10 minutes, and replated at 2.5 × 105 cells/cm2 into dishes pre-coated with 
polyornithine (15 µg/ml), laminin (1 µg/ml) and fibronectin (5 µg/ml) for 2 days. Quantification of 
neural precursors and MN was assessed by confocal microscopy/flow cytometry using anti-
NESTIN, anti-SOX2, anti-TUJ1, anti-ISL1, anti-HB9 and anti-NCAM antibodies, and qRT-PCR. 
Antibodies and primers used are detailed in Table S1 and S2.  
Skeletal muscle differentiation 
iPSC were differentiated into sleletal muscle (SkM) using the protocol described by Darabi et 
al.[33]. Briefly, iPSC were transduced with rtTA and iPAX7-GFP lentiviruses overnight and the 
medium was then changed to fresh MEF-CM. EBs were generated as described and plated on 
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low-attachment plates in MEF-CM medium with Y27632 (10 µM; d0-d7). After 2 days, the 
medium was replaced with myogenic induction medium (MIM) (IMDM, GlutaMax, 15% FBS, 10% 
horse serum and 1% P/S) supplemented with 1% Chicken Embryo Extract (US Biological), AA 
(25 µg/ml) and 1-monothioglycerol (0.45 mM; Sigma). At day 7, EBs were plated into 0.1% 
gelatin-coated flasks with MIM plus bFGF (10 ng/ml). Doxycycline (1 µg/ml; Sigma) was added 
from day 10 of differentiation onwards. Cells were treated with 10µM Y27632 24 hours before 
GFP sorting on a FACSAria Fusion cell sorter (BD), and sorted cells were replated at 2.5 × 105 
cells in a T-25 gelatin-coated flask (Fig 6A). PAX7 expression and GFP was confirmed 
immediately after sorting. PAX7+ muscle progenitors were grown in complete MIM with bFGF 
and doxycycline until passage 3. For further maturation, PAX7+ muscle progenitors were first 
plated at 1.5 × 104 cells/cm2. One day before confluency, cells were washed to remove 
doxycycline and were grown in MIM. At confluency, cells were grown in Differentiation Medium 
(KO DMEM, 20% KO Serum Replacement, 1% NEAA, 1% GlutaMax, and 1% P/S) for 12−14 
days. SkM differentiation was assessed by immunofluorescence using anti-PAX7 and anti-MYH1 
antibodies, and qRT-PCR. Primers and antibodies used are detailed in Table S1 and S2. Levels 
of creatine kinase in iPSC-derived SkM cells were measured using clinical standards in the 
biochemical diagnostic laboratory at the Clinic Hospital of Barcelona. 
CoQ10 biosynthesis, concentration, mitochondrial respiratory chain activity and metabolic 
measurements 
To measure CoQ10 biosynthesis, 13C6-p-hydroxybenzoic acid (PHB) was added to fibroblast and 
iPSC cultures for 48 hours. Cell pellets were then suspended in 300 µl of a solution containing 
0.25 mM sucrose, 2 mM EDTA, 10 mM Tris and 100 UI/ml heparin (pH 7.4), and sonicated twice 
for 5 sec. Homogenates were then used to determine CoQ10 biosynthesis as previously 
described [40]. The physiological content of CoQ10 in cultures was determined by HPLC with 
electrochemical detection as described [40, 41]. Activities of NADH:coenzyme Q1 
oxidoreductase (complex I), succinate dehydrogenase (complex II), ubiquinol:cytochrome c 
oxidoreductase (complex III), cytochrome c oxidase (complex IV), NADH:cytochrome c 
reductase (complex I+III), succinate:cytochrome c reductase (complex II+III) and citrate synthase 
(CS) were determined using described spectrophotometric methods[42].  
Live cell oxygen consumption (OCR) and extracellular acidification rate (ECAR) 
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OCR and ECAR were measured using the Seahorse Bioscience equipment (Agilent). CQ4- and 
CQ4-edited-iPSCs were seeded at density of 25x103 cells per well of a XF24 cell culture 
microplate and incubated for 48h. For OCR the cells were equilibrated with DMEM supplemented 
with 4,5g/L glucose, 1 mM sodium pyruvate and 2 mM glutamine. For ECAR, cells were 
maintained in DMEM supplemented with 2 mM glutamine. Mitochondrial processes were 
examined through sequential injections of oligomycin (4µM; ATP synthase inhibitor), carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; 2 µM; uncoupling agent), rotenone (1µM; 
CI inhibitor) and antimycin A (5µM; CIII inhibitor). Mitochondrial function was calculated upon 
subtracting the non-mitochondrial respiration background after the addiction of antimicyn A. The 
basal respiration rate (baseline OCR minus Antimycin A OCR), Proton Leak (oligomycin OCR 
minus Antimicyn A OCR). The glycolytic processes were examined through sequential injections 
of glucose (25mM), oligomycin (4µM), 2-Deoxy-D-glucose (2-DG; 50mM). The glycolysis rate 
was calculated upon subtracting the non-glycolytic acidification after the addiction of 2-DG. 
ATP and ROS measurements 
ATP levels were measured using a Cell-Titer-Glo® Luminescent Cell Viability Assay (Promega) 
according to the manufacturer’s guidelines. Briefly, equal numbers of cells (5x104/100 mL) were 
seeded in a 96-well plate and 100 mL of the reaction reagent were added to each well. After 10 
min shaking, the luminescence signal was detected using the Infinite®200PRO (Tecan) and 
compared against the ATP Standard Curve using ATP disodium salt (Promega) [43]. ROS 
generation was quantified by flow cytometry (FACS Canto-II) using CM-H2DCFDA (Life 
Technologies). 1x105 cells were incubated with 2 µM CM-H2DCFDA, with or without 0.3% H2O2 
to analyze the responsiveness to oxidative stress, and then incubated for 45min in the darkness. 
7-amino-actinomycin D (7-AAD) was added 10 min before FACS analysis. Intracellular ROS was 
measure in the live cells (7-AAD-). 
Proliferation, apoptosis, cell cycle analysis and senescence assays 
Proliferation of CQ4- and Ctrl-F was measured by growing cells in low-glucose DMEM with 20% 
FBS and 1% P/S. In total, 16 × 103 cells/cm2 were initially plated and counted every 7 days. For 
cell cycle analysis, cells were fixed in 70% ice-cold ethanol and stored at -20ºC. Subsequently, 
cells were washed with ice-cold PBS and suspended in propidium iodide buffer containing 
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RNAse (5 µg/ml) and 0.005% Triton X-100. Cell cycle distribution was analyzed on a FACS 
Canto-II cytometer using the FACSDiva and ModFit LT software packages (BD). 
Apoptosis was analyzed with the Annexin-V apoptosis Detection kit (BD), using annexin-V-PE 
and 7-AAD. Apoptotic cells were identified as Annexin-V+ while dead cells were 7-AAD+. The 
senescence-associated-galactosidase (SA-β-Gal) assay was performed as described[44]. 
Briefly, cells were fixed in 2% PFA/ 0.2% glutaraldehyde-PBS for 3 min at room temperature and 
then incubated with X-Gal-containing solution (ThermoFisher) for 15 hours at 37ºC in the dark. 
Positive cells were counted manually. 
Patch-clamp recordings  
For electrophysiological recordings, CQ4-iPSCs were differentiated into MN. MN were 
transduced with the MN-specific promoter HB9:GFP lentivirus (AddGene #37080). Whole-cell 
recordings were obtained from GFP+ MNs with an EPC-10 patch-clamp amplifier (HEKA GmbH, 
Germany) using standard voltage and current clamp protocols designed with Patch-Master 
software (HEKA). In voltage-clamp configuration, depolarizing voltage steps were applied from 
–50 mV to +70 mV. Action potentials were evoked by applying a pulse of current of variable 
amplitude (20-100 pA) to neurons in current-clamp configuration. Unless otherwise specified, 
holding potential was -70 mV. Data were filtered at 10 kHz, digitized at a sampling interval of 20 
µs and computarized. Off-line data analysis was performed using Igor6. Patch electrodes (2–3 
MΩ) were pulled from capillary glass tubes (1.5–1.6 mm OD; Kimax, Kimble Products) and fire-
polished on a microforge MF-830 (Narishige). All experiments were conducted at room 
temperature. The bath solution contained: NaCl 140mM, KCl 5mM, CaCl2 2mM, MgCl2 2mM, 
HEPES 10mM, Glucose 15mM (pH 7.4; osmolality 300-310 mOsm). The pipette solution 
contained: potassium gluconate (C6H11O7K) 120mM, KCl 20mM, NaCl 10mM, CaCl2 1mM, Mg-
ATP 4mM, Na-GTP 0.4mM, HEPES 10mM, EGTA 10mM and glucose 10mM (pH 7.2, osmolality 
280-290 mOsm).  
Determination of dopamine in differentiated neurons by HPLC. 
Spontaneous neurotransmitter release was measured in cell culture medium. Neurons were 
incubated as regularly in 1 ml/one 24-well of medium which was harvested at the time of medium 
changing. Samples corresponding to different clones and differentiation experiments were 
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collected between day 35 and 45 of differentiation and immediately stabilized by adding to each 
0.5ml sample 25 µl of stabilization solution (88 µl of 85% ortophosphoric acid, 4.4 mg of sodium 
metabisulfite and 912 µl of H2O). Samples were frozen in dry ice, and then stored at -80°C until 
measurement. Dopamine was extracted using a kit for purification of plasmatic catecholamines 
(Chromsystems, Germany) and 3,4-dihydroxybenzylamine (DHBA) was utilized as internal 
standard. Eluted samples were analyzed by a high-performance liquid chromatography (HPLC).  
Samples were analyzed with ALEXYS 100 (Antec Leyden, Zoeterwoude, The Netherlands) 
system equipped with a reverse phase C-18 column (3 µm particle size, 150 x 2.1 mm 
dimension), a glassy carbon electrode and an in situ ISAAC reference electrode (all from Antec 
Leyden). The amount of dopamine was expressed as pg per ml of sample. The meanSEM was 
plotted.  
DNA and RNA extraction and (qRT)-PCR  
DNA was obtained using the Maxwell 16 Blood DNA Purification kit (Promega). Isolation of total 
RNA was performed using RNAqueous-Micro kit (Ambion). The cDNA synthesized by using 
SuperScript III Reverse Trascriptase kit (Invitrogen). qRT-PCR was done using SyberGreen 
(Applied) and values were normalized to β-Actin or GAPDH. PCR conditions were 95ºC for 
10min, followed by 40 cycles of 95ºC for 15s and 60ºC for 60s.  
COQ4 mutation detection 
For genomic detection of the COQ4 mutation, a touchdown PCR was performed with 100ng of 
gDNA. PCR conditions were 1 cycle of 5 min at 95°C; 24 cycles of 30 sec at 95°C, 30 sec at 
62°C (-0.5°C per cycle), 1 min at 72°C; 6 cycles of 30 sec at 95°C, 30 sec at 50°C, 1 min at 
72°C; 1 cycle of 10 min at 72°C. PCRs were resolved in 1% agarose gels. Primers used to 
confirm the mutation on patient’s fibroblast and iPSC as well as primers used for Sanger 
sequencing are described in Table S1. 
Lentiviral transduction  
Hb9::GFP lentivector (AddGene #37080) [45] was used to transduce MN. iPAX7-pSAM2 and 
rTtA-pSAM lentivectors used for SkM specification were kindly provided by Prof. Rita Perlingeiro 
(University of Minnesota). Viral particles were generated on 293T cells by Polyethylenimine or 
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calcium phosphate transfection (along with psPAX2 and VSV-G helper plasmids) and 
concentrated by ultracentrifugation, as previously described [46, 47]. 
Immunofluorescence and confocal microscopy 
Cells were fixed with 2-4% PFA in PBS for 20 min at RT and washed 3 times with PBS. Antigen 
blocking was done with 6% donkey FBS with 0.5% Triton X-100. Cells were then washed and 
incubated at 4ºC overnight with the primary antibody diluted in blocking solution with 0.1% Triton 
X-100. After washing, cells were incubated with the secondary antibody for 2h at RT, washed 
and mounted with Vectashield (Vector Labs). Antibodies, dilutions and suppliers are on Table 
S2. The percentage of antibody positive cells at different time-points was determined in at least 
three independent experiments for each iPSC clone. At least five images were acquired with 
Leica TCS SP5 Confocal microscope from each different time-point analyzed. Images for 
quantification were selected randomly and each image was scored first for the number of DAPI 
positive nuclei, followed by counting the number of cells expressing the marker of interest. 
Manually counting was performed with ImageJ software. All data are presented as mean±SEM.  
Muscle histology and mitochondrial dynamics in muscle 
Healthy and diagnostic muscle biopsies were processed for histology and immunohistochemistry 
following standard procedures[48]. Muscle tissue was stained with hematoxylin and eosin, and 
the muscle/mitochondria-specific markers SDH, COX and trichrome[48, 49]. To assess 
mitochondrial dynamics, differentiating myogenic cells were stained with the mitochondrial import 
receptor subunit TOM20 and images were taken with a Leica TCS SP5 laser scanning confocal 
system with a 63× oil immersion objective[50]. At least 5 cells were randomly selected and 
analyzed for each experimental group. Image analysis was performed with ImageJ (NIH). The 
following parameters were measured to analyze mitochondrial dynamics. i) total number of 
mitochondria/cellular area[51]; ii) mitochondrial circularity (4π.area/perimeter2). Circular 
mitochondria exhibit reduced interaction with each other, therefore, the higher the value, the 
poorer the mitochondrial dynamics/function; iii) Form Factor (FF) (perimeter2/4π.area), which is 
the degree of mitochondrial branching. The higher the FF value, the more dynamic/functional 
mitochondria are; and iv) Aspect Ratio (major axis/minor axis), which measures the mitochondrial 
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elongation/length. More elongated/elliptical mitochondria have a higher AR, indicative of more 
dynamic/functional mitochondria. 
Statistical analysis 
Results are shown as mean±SEM and the normality of data was checked using the Kolmogorov–
Smirnov test. For variables with a normal distribution, Student’s t-test and one-way ANOVA were 
used to compare the significance of differences between experimental groups. For variables with 
no normal distribution, Mann-Whitney U-test or Kruskal-Wallis test was applied. Statistical 
analysis was performed using SPSS 18.0 software. A p-value<0.05 was considered significant. 
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RESULTS 
COQ4 mutation is linked to impaired mitochondrial function and CoQ10 deficiency 
A 4-year-old girl was diagnosed in our Institution with minor mental retardation and lethal 
rhabdomyolysis. Genetic analysis identified a heterozygous c.483 G>C mutation in the COQ4, 
leading to the amino acid change E161D (Fig 1A). COQ4 mutations have been reported to be 
responsible for severe early-onset mitochondrial diseases with heterogeneous clinical 
presentations and associated CoQ10 deficiency[22-24]. Analysis of fibroblasts revealed that the 
concentration and biosynthesis of CoQ10 was 75% and 87% lower, respectively, in CQ4-F than 
in Ctrl-F (Fig 1B, C). The expression of key COQ genes involved in CoQ10 biosynthesis was 
appreciably higher in CQ4-F than in Ctrl-F, suggestive of a transcriptional compensatory 
mechanism (Fig. 1D). In line with its role in electron transport, the reduction in CoQ10 in CQ4-F 
was reflected in the reduction of 41% and 64% in the activity of complex I+III and II+III, 
respectively (Fig 1E). CoQ10 is involved in pyrimidine biosynthesis, which is a requirement for 
cell proliferation [2, 5, 7]. Accordingly, cell proliferation was considerably lower in CQ4-F than in 
Ctrl-F (Fig 1F). Moreover, the proportion of cycling cells was lower for CQ4-F than for Ctrl-F 
(33% vs 24%; Fig 1G), and this was accompanied by a 17-fold increase in senescence as 
measured by SA-β-Gal staining, and a 2-fold increase in the level of the senescence-associated 
gene p16 (CDKN2A, Fig 1H). Conversely, the level of apoptosis was not different between CQ4-
F and Ctrl-F (Fig 1I). Histological analysis of the patient’s SkM revealed extensive damage 
associated with rhabdomyolysis (Fig 1J), as shown by disorganized tissue structure and loss of 
expression of the mitochondrial markers SDH and COX (Fig 1J). 
Generation and characterization of CQ4-iPSCs. 
CQ4-F were reprogrammed into hiPSCs in an attempt to model the metabolic and functional 
impact of COQ4 mutation on neural and muscle cell fate. Patient and control fibroblasts were 
transduced with OSKM-expressing Sendai virus (SeV) following the experimental design outlined 
in Fig 2A. iPSC colonies emerged 16–18 days after OSKM transduction and were picked for 
further characterization (Fig 2A). Reprogramming efficiency was ~5-fold higher in Ctrl-F than in 
CQ4-F (0.8% vs 0.17%, Fig 2B), likely reflecting the impaired proliferation capacity of CQ4-F. 
PCR analysis and Sanger sequencing confirmed the c.483 G>C mutation in all CQ4-iPSC clones 
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(Fig 2C). After 8–10 passages, iPSC lines were OSKM transgene independent as revealed by 
immunostaining and qRT-PCR analysis for SeV (Fig 2D). Characterization of iPSC lines 
revealed an embryonic stem cell (ESC)-like morphology and positive alkaline phosphatase 
staining (Fig S1A). In addition, the pluripotency-associated genes OCT4, SOX2, REX1, NANOG 
and CRIPTO were similarly expressed in Ctrl- and CQ4-iPSCs (Fig S1B). Similarly, 
immunocytological staining revealed bona fide expression of OCT4, NANOG, TRA-1-60 and 
SSEA4 in both CQ4- and Ctrl-iPSCs (Fig S1C). Endogenous expression of NANOG and OCT4 
was accompanied by the extensive loss of CpG methylation in their promoters (Fig S1D). Both 
Ctrl- and CQ4-iPSCs consistently displayed a diploid karyotype after >20 passages (Fig S1E), 
and formed teratoma in immunodeficient mice comprising tissue representing all three germ 
layers (Fig S1F). 
iPSC gene edition by CRISPR/Cas9 system. 
Because the differentiation capacity among iPSC lines is influenced by (epi)genetic variability[52, 
53], the optimal scenario to unravel genotype-phenotype associations is to use isogenic iPSC 
lines. We therefore used the CRISPR/Cas9 system to gene edit CQ4-iPSCs (CQ4ed-iPSCs). 
From the four sgRNAs designed surrounding the c.483 G>C mutation in exon 5 of the COQ4 
allele, one sgRNA was found to have a high cleavage activity (25%, data not shown) in the T7 
surveyor assay, cutting 8 nucleotides upstream of the mutation. Next, we designed a 90 bp-long 
donor ssDNA carrying a silent mutation for the generation of a Taqα1 restriction site and the 
mutation corrected codon (Fig 2E). CQ4-iPSCs were co-transfected with Cas9-GFP vector and 
ssDNA and, 2 days later, GFP+ clones were FACS-sorted as single cells. All individual GFP+ 
established clones were analyzed by PCR and restriction fragment length polymorphism, 
obtaining an allele digestion where the editing was performed (Fig 2F). Homozygous editing of 
the COQ4 mutation was observed in several clones, which was further confirmed by sequencing 
(Fig 2G). The top off-target predicted beforehand, GRID2, was sequenced in CQ4ed-iPSC lines 
and was consistently found to be in germline configuration, demonstrating the specificity of the 
sgRNA/gDNA used to edit the COQ4 mutation (Fig 2H). Importantly, CQ4ed-iPSCs remained 
pluripotent, as shown by typical ESC-like morphology, growth and by expression of pluripotency-
associated transcription factors (Fig 2I) and surface markers (Fig S1G), and was cytogenetically 
stable (Fig S1H). 
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COQ4 genome edition reverses metabolic/mitochondrial dysfunction   
CoQ10 is a lipophilic molecule involved in the MRC[1, 2], and low levels of CoQ10 in fibroblasts or 
muscle biopsies are linked to CoQ10 deficiency[16]. To obtain a reference value for CoQ10, we 
measured its concentration in different pluripotent stem cells (hESCs and hiPSCs) (Fig 3A left). 
CoQ10 concentration and biosynthesis was significantly lower (36% and 61%, respectively) in 
CQ4-iPSCs than in Ctrl-iPSCs and hESCs (Fig 3A right, 3B). Strikingly, a full restoration of both 
CoQ10 concentration (25% increase) and biosynthesis (50% increase) was found in CQ4ed-iPSCs 
(Fig 3C,D). Similarly, the activity of MRC complexes I+III and II+III was recovered in CQ4ed-
iPSCs (~50% increase) (Fig 3E). We next evaluated oxidative phosphorylation and glycolysis by 
ATP quantification, basal live-cell oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR). To produce the same ATP concentration (Fig 3F), CQ4-iPSCs ECAR (Fig 3G) and 
OCR (Fig 3H) rates were 2-fold higher than in CQ4ed-iPSCs, suggesting a respiration dysfunction 
as confirmed by a 2-fold higher proton leak (difference between oligomycin- and actinomycin A-
mediated inhibition of OCRs) in the mutated relative to edited iPSC lines (Fig 3I). Together, these 
results show that CQ4-iPSCs maintain the CoQ10 deficiency and metabolic dysfunction found in 
CQ4-F, which is reversed upon correction of the COQ4 mutation, thus directly linking c.483 G>C 
COQ4 with the dysfunctional metabolic phenotype. 
COQ4 mutation does not impair iPSC differentiation into dopaminergic or motor neurons  
The impact of COQ mutations in neurodevelopment remains unclear. The majority of CoQ10-
deficient patients present neurological symptoms [17, 18] whereas patient here described did not 
show neurological deficits other than a minor mental retardation we therefore studied the 
developmental influence of the COQ4 mutation in neurogenesis. Ctrl-, CQ4- and CQ4ed-iPSCs 
were differentiated into midbrain dopaminergic (DA) neurons and spinal motor neurons (MN) 
using well-established protocols (Fig 4A, 5A)[38, 39]. Successful differentiation was confirmed 
by flow cytometry as demonstrated by a progressive increase in the proportion of Neural Cell 
Adhesion Molecule (NCAM+) cells, with >80%  and >60%  of NCAM+ cells formed by day 30 of 
development, in the DA and MN differentiation respectively, irrespective of the iPSC genotype 
(Fig 4B, 5B). We then evaluated the differentiation output of neural progenitors (SOX2+NESTIN+) 
and immature neurons (TUJ1+) by confocal imaging at early time points (day 15–20 of neural 
induction). No differences were found between Ctrl- and CQ4-iPSCs for differentiation into neural 
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progenitors (50% and 35–50% SOX2+NESTIN+ cells under DA and MN differentiation 
conditions, respectively) or total neurons (15 and 22% TUJ1+ cells under DA and MN 
differentiation conditions, respectively) (Fig 4C, 5C). Similarly, at later time points (day 30–40 
of differentiation), the proportion of TUJ1+ differentiating neurons between Ctrl- and CQ4-iPSCs 
was very similar (30–40%) regardless of the differentiation protocol (Fig 4D, 5D). Furthermore, 
the yield of TUJ1+TH+ DA (8%) and TUJ1+HB9+/TUJ1+ISL1+ MN (4%) was also similar 
between Ctrl- and CQ4-iPSCs (Fig 4D, 5D). Accordingly, CQ4ed-iPSC differentiated into DA (Fig 
4C, D) and MN (Fig 5C, D) neurons as well as neural precursors to a similar extent to that 
achieved by CQ4-iPSCs. Immunofluorescence-based quantification was confirmed by qRT-PCR 
expression analysis of DA (FOXA2 and TH, Fig 4E) and MN (LHX3 and FOXP1, Fig 5E) master 
genes. We then carried out functional analyses to confirm these results. HPLC determination of 
dopamine release revealed very similar levels of dopamine in Ctrl- and CQ4-iPSC-derived 
neurons (Fig 4F). Whole-cell patch clamp recording of MN (identified using the HB9::GFP 
reporter)[39, 45] indicated that CQ4-iPSC-derived MN were electrophysiologically active, 
displaying inward and outward currents in voltage clamp and spontaneous action potentials 
suggestive of functional synapses after 40–50 days in culture. Moreover, induced action 
potentials and spontaneous firing were similar between Ctrl-iPSC and CQ4-iPSC-derived MN 
(Fig 5F)[45, 54]. The comparable yields of DA and MN generated from Ctrl-, CQ4- and CQ4ed-
iPSCs might be explained by similar neural specification from genotypically distinct iPSCs as no 
differences were found for cell death (Fig 4G, 5G) or cell cycle/proliferative status (Fig 4H, 5H) 
of the emerging NCAM+ cells. Of note, DA progenitors from CQ4-iPSCs cycled slightly less that 
those from Ctrl- or CQ4ed-iPSCs, possibly reflecting a role for COQ4 in the cell cycle of neural 
cells. Together, these data reveal that the c.483 G>C mutation in COQ4 does not impact DA or 
MN neurogenesis from iPSCs, recapitulating the patient’s phenotype. 
COQ4 mutation recapitulates the skeletal muscle functional and metabolic defects 
Muscle impairment is common in CoQ10-deficient patients[19], but it was especially life-threating 
in the patient reported here, who suffered from lethal rhabdomyolysis that was clinically 
unmanageable, resulting in her death from fatal kidney damage as a result of myoglobinuria. To 
study the developmental and metabolic impact of the COQ4 mutation in skeletal myogenesis, 
Ctrl-, CQ4- and CQ4ed-iPSCs were differentiated into SkM following a well-established protocol 
developed in the Perlingeiro laboratory[33]. Transgenic Ctrl-, CQ4- and CQ4ed-iPSC lines 
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carrying a PAX7-GFP-expressing inducible lentivector were generated, and myogenic 
specification was induced as described in Fig 6A. PAX7-GFP-expressing myogenic progenitors 
were GFP FACS-purified on day 15 of myogenic development (Fig 6A,B). All FACS-sorted GFP+ 
cells co-expressed PAX7, demonstrating the reliability of the inducible reporter (Fig 6C). 
Although the cell cycle profile (Fig 6D) and the level of apoptosis (Fig 6E) were very similar 
between CQ4- and Ctrl-PAX7+ myogenic progenitors, the number of senescent CQ4-PAX7+ cells 
was 2-fold higher, a phenotype that was corrected in CQ4ed-PAX7+ myogenic progenitors (Fig 
6F). The enhanced senescence observed in CQ4-PAX7+ myogenic progenitors might be 
explained by their increased ROS production (Fig 6G) leading to a 1-log reduction in cell 
expansion (Fig 6H); both of these functional properties were corrected in CQ4ed-PAX7+ 
myogenic progenitors (Fig 6G,H). 
PAX7+ myogenic progenitors were allowed to further differentiate into differentiated muscle cells 
(i.e. myocytes) as detailed in Fig 6A[33]. Consistent with the muscle damage observed in the 
CQ4-mutated patient, CQ4-PAX7+ myogenic progenitors displayed a significant maturation 
impairment as revealed by a 30% reduction in the generation of fully differentiated myosin heavy 
chain-1 (MYH1)+ cells (Fig 6I) and a 3-fold reduction in the expression of creatine kinase (CK) 
(Fig 6J), a master enzyme expressed in SkM that ensures an energy reservoir for the rapid 
buffering and regeneration of ATP. Importantly, both the generation of MYH1+ cells and the levels 
of CK were at control levels in differentiated muscle cells derived from CQ4ed-PAX7+ myogenic 
progenitors (Fig 6I,J). In addition, gene expression analysis of the specific myogenic markers, 
myogenic regulatory factor MYF5, myogenin (MGN) and myosin heavy chain 3 (MYH3), showed 
that their kinetics of expression were deregulated in CQ4-PAX7+ as compared with Ctrl-PAX7+ 
differentiating muscle cells (Fig 6K). Because MYF5 is exclusively expressed in proliferating 
myogenic cells and MGN is an early differentiation marker[55], their enhanced expression in 
CQ4-PAX7+ versus Ctrl-PAX7+ cells supports the delayed entry into full differentiation of patient-
derived CQ4-PAX7+ cells; of note, the expression kinetics of these genes returned to control 
values in CQ4ed-PAX7+ differentiating cells (Fig 6K). 
Finally, we analyzed the metabolic impact of the COQ4 mutation in SkM derivatives generated 
from Ctrl-, CQ4- and CQ4ed-PAX7+ myogenic progenitors. Consistent with the patient’s 
phenotype, morphometric image analysis muscle cells stained with TOM20 revealed 
abnormalities in mitochondrial morphology caused by the COQ4 mutation (Fig 6L). Accordingly, 
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CQ4-PAX7+ iPSC-derived differentiated muscle cells had smaller (nº mitochondria/cellular area, 
Fig 6L-panel i), more circular (Fig 6L-panel ii), less branched (FF, Fig 6L-panel iii), and shorter 
(mitochondrial length, Fig 6L-panel iv) mitochondria than Ctrl-PAX7+ iPSC-derived differentiated 
muscle cells[56]. Importantly, these mitochondrial dynamics-associated parameters were 
restored in CQ4ed-PAX7+ iPSC-derived differentiated muscle cells. In addition, MRC complex 
I+III activity was 50% lower in CQ4-PAX7+ iPSC-derived differentiated muscle cells than in Ctrl-
PAX7+ counterparts, and this was fully restored in CQ4ed-PAX7+ iPSC-derived differentiated 
cells, (Fig 6M). Collectively, these results establish the utility of an iPSC-based disease model 
to study CoQ10 deficiency, wherein the COQ4 mutation faithfully reproduces the disease-
associated SkM functional and metabolic defects.   
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DISCUSSION 
CoQ10 deficiency comprises a growing number of metabolic disorders with neurological and 
extraneurological manifestation. Despite being considered a rare disease, next-generation DNA 
sequencing techniques coupled with well-established biochemical determination of CoQ10 
biosynthesis has allowed the identification of a variety of primary and secondary CoQ10 
deficiencies[57]. Primary deficiency of CoQ10 is an autosomal recessive syndrome originating 
from mutations in genes responsible for CoQ10 biosynthesis. The pathogenesis of secondary 
CoQ10 deficiency is less studied but may be linked to assembly defects in oxidative 
phosphorylation (OxPhos) complexes/metabolic pathways[19, 58]. CoQ10 deficiency impairs 
OxPhos and global metabolic homeostasis, ultimately causing clinically heterogeneous 
mitochondrial diseases in primarily SkM and central nervous system, likely because the 
disruption of energy metabolism strongly affects tissues with high-energy demand[8, 59].  
It has been recently suggested that COQ4 has an essential structural and functional role for the 
biosynthesis of CoQ10, and COQ4 mutations as well as COQ4 haploinsufficiency cause a broad 
spectrum of mitochondrial disorders associated with CoQ10 deficiency[19-24]. Here, we report a 
4-year-old girl with a heterozygous c.483 G>C mutation in COQ4 who displayed severe 
metabolic/mitochondrial deficits, extensive muscle damage and lethal rhabdomyolysis. The 
COQ4 mutation was associated with CoQ10 deficiency and MRC dysfunction, in line with the 
critical role of CoQ10 as an electron shuttle. CQ4-mutated fibroblasts had a strongly impaired 
proliferative capacity linked to high senescence rates and a reduction in the proportion of cycling 
cells, reflecting the involvement of CoQ10 in pyrimidine synthesis [2, 5, 7]. A limitation of this work 
is that whether or not the COQ4 E161D allele is pathogenic on its own cannot be fully inferred 
from our study. It could represent a nucleotide variation with functional consequences. It might 
for instance be a genetic modifier of another yet unknown driver pathogenic mutation, which 
could account for the increased susceptibility of the patient to develop CoQ10 deficiency in 
association with COQ4 E161D. Further genetic and functional studies on a larger patient cohort 
should be performed to address whether COQ4 E161D allele may be a triggering factor which 
modifies the phenotype of different diseases. 
A major obstacle to study this disorder is the lack of genotype-phenotype association. Human 
diseases are generally studied once the full (epi)genetic events (i.e. mutations) are already in 
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place and, therefore, the mechanisms of disease pathophysiology are not amenable to analysis 
with primary patient samples. Patient-specific iPSCs can serve to model human disease since 
their re-differentiation potential provides a unique strategy to explore the developmental impact 
of disease-specific mutations on human stem cell fate, especially in early-onset or developmental 
diseases[28, 60, 61]. We generated and CRISPR/Cas9 corrected iPSCs from a patient with a 
mutation in COQ4 in an attempt to model its impact on MRC/mitochondrial activity and neural 
and skeletal muscle development. Of note, COQ4-mutated cells were less efficiently 
reprogrammed, likely reflecting the impaired proliferation of CQ4-F. Nevertheless, 
undifferentiated CQ4-iPSCs were functionally indistinguishable from Ctrl-iPSCs. 
We show for the first time the levels of CoQ10 in a panel of pluripotent stem cell lines. Interestingly, 
cell reprogramming failed to reestablish CoQ10 levels/biosynthesis in mutated cells, but this were 
fully restored upon COQ4 correction, demonstrating the causal effect of c.483G>C COQ4 
mutation in the metabolic dysfunctional phenotype associated with CoQ10 deficiency. This data 
together with previous data in yeast[20, 62, 63] may highlight the evolutionary conserved role of 
CoQ10 in mitochondrial function by regulating OxPhos and ultimately ATP synthesis. Indeed, 
MRC complexes I+III and II+III, OxPhos, and glycolysis were all severely impaired in CQ4-iPSC, 
which required a 2-fold increase in OCR and ECAR to generate the same concentration of ATP. 
The increased proton leak in CQ4-iPSC represents ATP-independent respiration and an 
increase in the passive leak of protons from the inner mitochondrial membrane, linking CoQ10 
with proton shuttling in pluripotent stem cells [60]. 
Neurological manifestations are very common in CoQ10-deficient patients[16-18]. Interestingly, 
our patient failed to exhibit neurological symptoms other than modest mental retardation. 
Because the impact of COQ mutations in neurodevelopment remains unclear, we studied the 
developmental influence of the COQ4 mutation in neurogenesis using well-established protocols. 
Our analysis revealed that the c.483 G>C mutation in COQ4 does not impact iPSC differentiation 
of central nervous system neurons (midbrain DA and spinal MN), thus recapitulating the patient’s 
normal neurological phenotype and suggesting that mutations in COQ4 do not influence neural 
specification from PSCs. 
Life-threating rhabdomyolysis was severe in this patient, and eventually led to myoglobinuria and 
nephrotic toxicity, causing the patient’s death. We used a sophisticated differentiation strategy 
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to generate SkM from iPSC, which proceeds through an initial myogenic induction based on the 
generation of PAX7+ myogenic progenitors, and subsequent maturation into muscle cells [33]. 
Our data clearly show that CQ4-iPSC-differentiated SkM recapitulates CoQ10 deficiency-
associated SkM functional and metabolic defects. First, CQ4-PAX7+ myogenic progenitors 
exhibited 1-log reduced cell expansion within a 15-day period, associated with increased levels 
of senescence, which might likely be due to the increased ROS levels produced. These 
dysfunctional properties were corrected in genome-edited PAX7+ myogenic progenitors. Second, 
maturation of CQ4-PAX7+ myogenic progenitors was lower than in Ctrl-PAX7+ counterparts. The 
generation of fully differentiated MYH1+ cells and the expression of CK, a master SkM enzyme 
for the rapid buffering and regeneration of ATP, were decreased significantly, and this was in 
agreement with the increased expression of myogenic cell proliferation/early differentiation 
markers. These parameters were recovered in muscle cells from CQ4ed-PAX7+ cells, 
demonstrating the causal link of c.483G>C COQ4 mutation in the impaired myogenic 
development and reproducing the main phenotypic manifestation of the disease. Third, 
mitochondrial morphometric imaging and analysis of MRC activity revealed abnormalities in 
mitochondrial morphology and a 50% decrease in the activity of MRC complex I+III, indicating 
that the COQ4 mutation negatively impacts the mitochondrial/metabolic function of iPSC-derived 
SkM derivatives generated from PAX7+ myogenic progenitors. These mitochondrial dynamics-
associated parameters and MRC complexes activity were restored in CQ4ed-PAX7+ iPSC-
derived differentiated muscle cells. Thus, genetic correction of COQ4 mutation rescued the 
mitochondrial function of COQ4-mutated SkM. 
In summary, we have established a patient-specific iPSC-based disease model for CoQ10 
deficiency associated to a heterozygous missense mutation in COQ4. Our findings provide 
evidence that the COQ4 mutation faithfully reproduces SkM dysfunction and metabolic deficits 
with no neurological involvement. This may assist in the study of complex genotype-phenotype 
associations observed in CoQ10 deficiency, opening avenues for testing new drugs to treat CoQ10 
deficiency. 
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FIGURE LEGENDS 
Figure 1: Biochemical, metabolic, proliferative and histological characterization of COQ4-
mutated fibroblasts. (A) Sanger DNA sequencing confirming the heterozygous c.483 G>C 
mutation in the patient’s fibroblasts. (B) Seventy-five percent reduction in [CoQ10] in CQ4-F 
relative to Ctrl-F. (C) Eighty-seven percent reduction in CoQ10 biosynthesis in CQ4-F relative to 
Ctrl-F. (D) qRT-PCR reflecting a higher expression of COQ3, COQ4 and COQ6 genes in CQ4-
F than in Ctrl-F (n=3). (E) Defective MRC complex I+III and II+III activities relative to citrate 
synthase in CQ4-F. (F) Fibroblast proliferation of Ctrl-F and CQ4-F (n=3); *p-value <0.01. (G) 
Cell cycle analysis of Ctrl-F and CQ4-F (n=3). (H) Senescence-associated β-galactosidase 
quantification of Ctrl-F and CQ4-F and representative image (4×) (left panel), and qRT-PCR 
expression of p16/CDKN2A (right panel) (n=3). (I) FACS quantification of apoptotic cells 
(Annexin V+, n=3). (J) Patient’s muscle histology revealing mitochondrial alterations after 
rhabdomyolysis. Values are expressed as mean±SEM. CQ4-F: COQ4 mutated primary 
fibroblasts; Ctrl-F: Control primary fibroblasts; H&E: Hematoxylin and eosin; SDH: Succinate 
dehydrogenase; COX: Cytochrome c oxidase. 
Figure 2: Generation of COQ4-mutated iPSCs and CRISPR/Cas9-mediated gene edition. 
(A) Schematic outline of the reprogramming process. (B) Reprogramming efficiency for Ctrl-F 
and CQ4-F. (C) PCR and sequencing confirming the presence of COQ4-mutated allele in several 
representative CQ4-iPSC clones. (D) Immunostaining confirming high-level infection with SeV 
48 h post-transduction and SeV elimination on all iPSC clones at p8-10 (left panel). qPCR 
reflecting complete absence of SeV at p8-10 (right panel). (E) Schematic overview for the 
strategy of CRISPR/Cas9 mediated targeting to the COQ4 locus. Sequence and synonymous 
modifications in the ssDNA. (F) Identification of edited iPSC clones by Taqα1 allele digestion in 
the genomic DNA after single cell cloning. (G) Sanger DNA sequencing confirming the gene 
edition. (H) Sanger DNA sequencing of the major predicted off-target GRID2 gene. (I) qRT-PCR 
for the pluripotency genes OCT4, SOX2, REX1, NANOG, CRIPTO and DNMT3β in hESC and 
CQ4ed-iPSC (n=3). Values are expressed as mean±SEM. CQ4-F: COQ4 mutated primary 
fibroblasts; Ctrl-F: Control primary fibroblasts; CQ4-iPSC: COQ4 mutated iPSC; Ctrl-iPSC: 
Control iPSC; CQ4ed-iPSC: COQ4-edited iPSC. 
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Figure 3: Genome editing of c.483 G>C COQ4 mutation reverses CoQ10 deficiency and 
metabolic dysfunction retained in CQ4-iPSCs. (A) Left, concentration of CoQ10 in a panel of 
hESC (H9, AND1), fibroblast-derived iPSC and blood-derived iPSCs (●), Ctrl-iPSCs (■) and 
CQ4-iPSCs (▲). Solid line represents the mean; dotted lines represent the range. Right, 
summary of [CoQ10] in hESCs (n=2), Ctrl-iPSCs (n=14) and CQ4-iPSCs (n=9). (B) Sixty-one 
percent reduction in CoQ10 biosynthesis in CQ4-iPSCs (n=9) relative to Ctrl-iPSCs (n=14). (C) 
[CoQ10] in mutated and edited CQ4-iPSCs. (D) CoQ10 biosynthesis in mutated and edited CQ4-
iPSCs. (E) MRC complex I+III and II+III activities relative to citrate synthase in mutated and 
edited CQ4-iPSCs. (F) [ATP] from mutated (n=6) and edited CQ4-iPSCs (n=6). (G) Glycolysis-
associated extracellular acidification rate (ECAR) under basal conditions in mutated (n=4) and 
edited CQ4-iPSCs (n=4). (H) Oxygen consumption rate (OCR) under basal conditions in mutated 
(n=6) and edited CQ4-iPSCs (n=6). (I) OCR proton leak under basal conditions in mutated and 
edited CQ4-iPSCs (n=4). Values are expressed as mean±SEM. Ctrl-iPSCs: Control iPSCs; 
CQ4-iPSCs: COQ4 mutated iPSCs; Fib-iPSCs: fibroblast-derived iPSCs; CB-iPSCs: cord blood-
derived iPSCs; Tcell-iPSCs: T cell-derived iPSCs. 
Figure 4: Dopaminergic (DA) differentiation of Ctrl-iPSCs, CQ4-iPSCs and CQ4-edited 
iPSCs. (A) Top, scheme of neuronal differentiation depicting two stages: neural induction (up to 
day 15–20) and neuronal maturation (up to day 33–44). Bottom, detailed differentiation protocol 
used. (B) Flow cytometry quantification of NCAM+ cells throughout DA differentiation (n=3). (C) 
Analysis of SOX2+NESTIN+ neural progenitors (top panels, N=42) and TUJ1+ neurons (bottom 
panels, N=49) from 5 iPSC clones. Left, differentiation efficiency in Ctrl-iPSCs (n=2) and CQ4-
iPSCs (n=3) at day 15–20 of iPSC differentiation. Middle, DA differentiation efficiency in mutated 
and edited CQ4-iPSCs. Right, representative images of immunostaining (40×) and magnification 
for SOX2+NESTIN+ and TUJ1+ cells. White arrows point to positive cells. Scale bar, 50 µm. (D) 
Analysis of the TUJ1+ neurons (top panels, N=51) and TH+TUJ1+ DA (bottom panels, N=48). 
Left, differentiation efficiency in Ctrl-iPSCs and CQ4-iPSCs at day 33–44 of iPSC development 
(n=5). Middle, DA differentiation efficiency in mutated and edited CQ4-iPSCs. Right, 
representative image of immunostaining (40×) and magnification for TUJ1+ and TUJ1+TH+ cells. 
White arrows point to positive cells. Scale bar, 50 µm. (E) Expression of the ventral midbrain 
marker gene FOXA2 after 15–20 days and the DA master gene TH after 33–44 days in 
differentiating Ctrl-, CQ4- and CQ4ed-iPSC cultures (n=3). (F) Representative HPLC 
chromatogram (left) and levels (right) of dopamine release in vitro from differentiating Ctrl-, CQ4- 
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and CQ4ed- iPSC cultures (n=2). (G) FACS quantification of dead cells (7-AAD+) within the 
NCAM+ neural population at day 15–20 of iPSC differentiation (n=3). (H) Cell cycle analysis 
(G2/S/M) within the NCAM+ population at day 15–20 of iPSC differentiation (n=3). Data are 
presented as mean±SEM. A total of six iPSC clones (three mutated and three control/edited) 
were used. 
Figure 5: Motor neuron (MN) differentiation from Ctrl-iPSCs, CQ4-iPSCs and CQ4-edited 
iPSCs. (A) Top, scheme of neuronal differentiation depicting two stages: neural induction (up to 
day 15–20) and neuronal maturation (up to day 30). Bottom, detailed differentiation protocol 
used. (B) Flow cytometry quantification of NCAM+ cells throughout MN differentiation. (C) 
Analysis of the SOX2+NESTIN2+ neural progenitors (top panels, N=43) and TUJ1+ neurons 
(bottom panels, N=46). Left, differentiation efficiency in Ctrl-iPSCs and CQ4-iPSCs at day 15–
20 of iPSC differentiation. Middle, MN differentiation efficiency in mutated and edited CQ4-
iPSCs. Right, representative images of immunostaining (40×) and magnification for 
SOX2+NESTIN+ and TUJ1+ cells. White arrows point to positive cells. Scale bar, 50 µm. (D) 
Analysis of the TUJ1+ neurons (top panels, N=26) and HB9+ or ISL1+ MN (bottom panels, N=21). 
Left, differentiation efficiency in Ctrl-iPSC and CQ4-iPSCs at day 30 of iPSC development. 
Middle, MN differentiation efficiency in mutated and edited CQ4-iPSCs. Right, representative 
images of immunostaining (40×) and magnification for TUJ1+ and TUJ1+ISL1+. White arrows 
point to positive cells. Scale bar, 50 µm. (E) Expression of the MN master genes LHX3 and 
FOXP1 after 30 days in differentiating Ctrl-, CQ4- and CQ4ed-iPSC cultures (n=3). (F)  
Representative electrophysiological analysis of MNs differentiated from CQ4-iPSCs (n=2). GFP+ 
MNs were recorded 4–7 days after transfection with a HB9 promoter-GFP reporter. (i) voltage-
dependent K+ and Na+ currents recorded at various membrane potentials. The holding potential 
was -70 mV; (ii) Current-clamp recording of action potentials evoked by current injection; (iii) 
Spontaneous action potentials in MNs recorded in the whole-cell current-clamp configuration. 
(G) FACS quantification of dead cells (7-AAD+) within the NCAM+ neural population at day 15–
20 of iPSC differentiation (n=3). (H) Cell cycle analysis (G2/S/M) within the NCAM+ population 
at day 15–20 of iPSC differentiation (n=3). Data are presented as mean ±SEM. A total of six 
iPSC clones (three mutated and three control/edited) were used. 
Figure 6: Impaired skeletal muscle differentiation of CQ4-iPSCs is restored upon COQ4 
gene editing. (A) Top, scheme of myogenic differentiation depicting two stages: myogenic 
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induction (up to day 15) and differentiation into myocytes (and further fusion into myotubes) from 
PAX7+ myogenic progenitors (up to day 30). Bottom, detailed differentiation protocol used for 
myogenic induction. (B) Representative FACS profile showing PAX7-GFP reporter expression 
in dox-treated iPSCs. (C) Immunostaining (20×) for PAX7+GFP+ FACS-purified CQ4-mutated 
myogenic progenitors. Scale bar, 200 µm. (D) FACS quantification of cycling cells (G2/S/M) 
(n=3). (E) FACS quantification of apoptotic cells (Annexin V+) (n=3). (F) Senescence-associated 
-galactosidase quantification of myogenic derivatives, and representative image (4X) (n=). Black 
arrowheads point to β-gal-positive cells. (G) Determination of ROS levels by flow cytometry 
(n=3). (H) Expansion of PAX7+ myogenic progenitors (n=3). (I) Left, analysis of MYH1+ myotubes 
differentiation in Ctrl-, CQ4- and CQ4ed- PAX7 cultures (n=3). Representative images of MYH1+ 
immunostaining at low (middle) and high (right) magnification of CQ4-mutated muscle cells. 
Scale bar, 200 µm. (J) Creatine kinase fold-increase between day 0 and day 11 of differentiation 
in Ctrl-, CQ4- and CQ4ed- PAX7 myogenic cells (n=6). (K) Expression of the SkM-specific genes 
MYF5, MGN and MYH3 throughout the myogenic differentiation process (n=3). Values are 
expressed as mean±SEM; *p<0.05. The shadow below the graph indicates the temporal 
expression pattern for each gene during myogenesis. (L) Top, mitochondrial dynamics for 
myogenic cells: (i) number of mitochondria/cellular area; (ii) mitochondrial circularity 
(4π.area/perimeter2); (iii) Form Factor (Degree of mitochondrial branching); and (iv) Aspect Ratio 
(mitochondrial length). Bottom, representative images of Ctrl-, CQ4- and CQ4ed- PAX7 myogenic 
cells stained with TOM20. (M) MRC complex I+III and II+III activities relative to citrate synthase 
in Ctrl-, CQ4- and CQ4ed- PAX7 myogenic cells (n=3). Data are presented as mean±SEM. 
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SUPPLEMENTAL FIGURE LEGENDS 
Figure S1: Characterization of iPSC. (A) Representative morphology and alkaline 
phosphatase staining of Ctrl-iPSC and CQ4-iPSC. (B) qRT-PCR for the pluripotency genes 
OCT4, SOX2, REX1, NANOG, CRIPTO in hESCs, Ctrl-iPSC and CQ4-iPSC. (C) Representative 
immunostaining for the pluripotency markers OCT4, SSEA-4, NANOG, TRA-1-60 in Ctrl-iPSCs 
and CQ4-iPSCs. (D) Pyrosequencing revealing demethylation of NANOG and OCT4 promoters 
in Ctrl-iPSCs and CQ4-iPSCs as compared to original fibroblasts. (E) Diploid karyotype of Ctrl-
iPSC and CQ4-iPSC at p20. (F) Teratoma analysis revealing three germ layer differentiation of 
Ctrl-iPSC and CQ4-iPSC. (G) Flow cytometry for the pluripotency markers SSEA-3, SSEA-4, 
TRA-1-60, TRA-1-81 in CQ4ed-iPSC. (H) Diploid karyotype of the CQ4ed-iPSC. Values are 
expressed as mean±SEM; *p<0.001. 
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Table S1: Primers used in this study 
Pyrosequencing  
NANOG-FW 5´-TATTGGGATTATAGGGGTGGGTTA-3´ 
NANOG-RV 5´-[Btn]-CCCAACAACAAATACTTCTAAATTCAC-3´ 
S-NANOG 5´-ATAGGGGTGGGTTAT-3´ 
OCT4_Prox-FW 5´- GGGGTTAGAGGTTAAGGTTAGTG-3´ 
OCT4_prox-RV 5´-[Btn]-ACCCCCCTAACCCATCAC-3´ 
S-OCT4_prox 5´-GGGGTTGAGTAGTTT-3´ 
OCT4_dist-FW 5´- TTTTTGTGGGGGATTTGTATTGA-3´ 
OCT4_dist-RV 5´-[Btn]- AAACTACTCAACCCCTCTCT-3´ 
S-OCT4_dist 5´-ATTTGTATTGAGGTTTTGGA-3´ 
  
qRT-PCR  
SeV-Fw GGATCACTAGGTGATATCGAGC 
SeV-RV ACCAGACAAGAGTTTAAGAGATATGTATC 
OCT4-FW GGGTTTTTGGGATTAAGTTCTTCA 
OCT4-RV GCCCCCACCCTTTGTGTT 
REX1-FW CCTGCAGGCGGAAATAGAAC 
REX1-RV GCACACATAGCCATCACATAAGG 
NANOG-FW ACAACTGGCCGAAGAATAGCA 
NANOG-RV GGTTCCCAGTCGGGTTCAC 
SOX2-FW CAAAAATGGCCATGCAGGTT 
SOX2-RV AGTTGGGATCGAACAAAAGCTATT 
CRIPTO-FW CGGAACTGTGAGCACGATGT 
CRIPTO-RV GGGCAGCCAGGTGTCATG 
DNMT3β-FW GCTCACAGGGCCCGATACTT 
DNMT3β-RV GCAGTCCTGCAGCTCGAGTTTA 
β –ACTIN-FW GATGGCCACGGCTGCTT 
β –ACTIN-RV AGGACTCCATGCCCAGGAA 
FOXA2-FW ATTGCTGGTCGTTTGTTGTG 
FOXA2-RV TGTACGTGTTCATGCCGTTC 
TH-FW GAGTACACCGCCGAGGAGATTG 
TH-RV GCGGATATACTGGGTGCACTGG 
LHX3-FW GTTCAGGAGGGGCAGGAC 
LHX3-RV CCCAAGCTCCCGTAGAGG 
FOXP1-FW TGACCTTTTGAGGTGACTATAACTG 
FOXP1-RV TGGCTGAACCGTTACTTTTTG 
CDKN2A-FW GGGTCGGGTAGAGGAGGTG 
CDKN2A-RV ACCGTAACTATTCGGTGCGT 
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COQ3-FW TGAACCTCTAGGGCGGCTTG 
COQ3-RV TCCAGGGAACACACTCTGTACTC 
COQ4-FW CTGTCCTCCGTCGGCTCTG 
COQ4-RV GCGGTGTCCTGTGGTCTCC 
COQ6-FW GTCTGCTGTTGTGGCTACTCTG 
COQ6-RV GGACCAAACCAAGGAACTCAAGG 
GAPDH-FW ACCACAGTCCATGCCATCAC 
GAPDH-RV TCCACCACCCTGTTGCTGT 
MYF5-FW GAGGTGTACCACGACCAACC 
MYF5-RV CCTGCTCTCTCAGCAACTCC 
MGN-FW CCAGGGGATCATCTGCTCACG 
MGN-RV GGTTTCATCTGGGAAGGCCA 
MYH3-FW CTTGTGGGCGGAGGTCTGG 
MYH3-RV AGCAGCTATGCCGAACACTT 
  
Genome editing  
T7-Fw GTAGAGACAGGGTTTCACCG 
T7-Rv GGACAGCCTCAAACCATTTC 
gRNA #1-FW CACCGCGTATGTGATTCAGCGGTAC 
gRNA #1-RV AAACGTACCGCTGAATCACATACGC 
gRNA #2-FW CACCGTGTGATTCAGCGGTACCGGG 
gRNA #2-RV AAACCCCGGTACCGCTGAATCACAC 
gRNA #3-FW CACCGTCATCATCCACGAAGCGGGT 
gRNA #3-RV AAACACCCGCTTCGTGGATGATGAC 
gRNA #7-FW CACCGCTCATCATCCACGAAGCGGG 
gRNA #7-RV AAACCCCGCTTCGTGGATGATGAGC 
ssDNA donor 
GTTGGTGGGCATCCCCAGCAGGGTGTGAAGCATG
TCGTGCACCTCTCGATACCGCTGAATCACATACGC
TAGCTCCTCATCATCCACGAAGCGGGTGGG 
  
Sequencing  
COQ4-FW CTGGGAACCATCAGGAAGG 
COQ4-RV CCAAGAGTGAACAGAAGGGAG 
COQ4-Mut-FW ATTCAGCGGTACCGGGAC 
SEQ-COQ4-FW CCAGACACCCGAGCACCC 
SEQ-COQ4-RV AGAAGGGAGTAGGGGATGGA 
T7-Fw GTAGAGACAGGGTTTCACCG 
T7-Rv GGACAGCCTCAAACCATTTC 
EXON5 COQ4-Rv ATGCAGAGGGTGGTGGAGATAG 
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Table S2: Primary and secondary antibodies used in this study 
Antibody Supplier Reference Dilution 
OCT-4 ABCAM AB19857 1:500 
SSEA-4 ABCAM AB16287 1:50 
NANOG ABCAM AB21624 1:50 
TRA-1-60 ABCAM AB16288 1:50 
Alexa Fluor® 488 α-Rabbit Jackson ImmunoResearch 711-545-152 1:500 
Alexa Fluor® 555 α-Mouse Life Technologies A31570 1:500 
Alexa Fluor® 594 α-Mouse Life Technologies A11032 1:500 
Alexa Fluor® 647 α-Goat Life Technologies A21447 1:500 
NESTIN Neuromics MO15012 1:300 
TUJ1 Covance mms-435p 1:500 
TUJ1 Covance mrb-435p 1:500 
TH Pel-Freez p40101 1:1000 
SOX2 Neuromics GT26098 1:500 
HB9 DSHB 81.5C10 1:5 
ISL1 DSHB 39.4D5 1:5 
CD56-V450 (NCAM) BD Horizon 561984 1:100 
PAX7 DSHB PAX7 1:10 
MYH1 (MF20) DSHB MF 20 1:10 
TOM20 (FL-145) SantaCruz sc-11415 1:500 
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VI. DISCUSSION 
Mitochondria are multifunctional organelles that play a pivotal role in the cell by 
providing most of the cellular energy and regulating cell death and proliferation, 
signaling and differentiation [105, 136, 207-209]. In this study, we first gained insights 
into the contribution of mitochondrial function/mass for hematopoietic stem versus 
progenitor function. We then used an iPSC model to explore the consequences of CoQ10 
deficiency through an analysis of the metabolic and developmental impact of a COQ4 
mutation during differentiation of iPSCs into tissues affected by COQ10.   
I. Contribution of mitochondrial function/mass in hematopoietic stem 
versus progenitor function. 
Hematopoiesis is a dynamic process that ensures homeostasis of the blood/immune 
system by maintaining the equilibrium between cell formation and differentiation and 
cell death. HSPCs are functional reservoirs at the top of the hematopoiesis hierarchy 
that replenish the hematopoietic system upon physiological demands. The size of a stem 
cell population depends on the balance between self-renewal and differentiation. 
Although principally driven by genetic and epigenetic networks, metabolic pathways 
have recently been linked to this finely tuned regulation. Accordingly, recent work has 
categorized stem cell populations based on their mitochondrial function [51, 53, 54, 
210]. HSCs are classified as being in either quiescent or cycling states, with quiescence 
viewed as a defense mechanism against the accumulation of damage resulting from 
physiological/oxidative stress [51, 52]. Generally, quiescent HSCs are enriched in LT-
HSCs as shown by their capacity to long-term reconstitute lethally irradiated mice. By 
contrast, ST-HSCs are mainly cycling cells responsible for the maintenance of 
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hematopoietic homeostasis during shorter time periods. Human HPCs are the 
counterparts of mouse ST-HSCs and are enriched in hematopoietic clonogenic capacity 
when cultured in semisolid media [7, 59, 211]. The metabolic activity of quiescent 
HSCs is lower than that of cycling HSCs, but increases when they exit from quiescence. 
This exceptional property is determined by a unique vascular organization of the BM 
with limited oxygen availability that provides a protective microenvironment for LT-
HSCs from oxidative stress and DNA damage [52]. Mechanistically, LT-HSCs reside 
in a hypoxic niche, which is permissive to maintain cells in a non-dividing state and 
prevent the detrimental accumulation of ROS. HSCs are glycolytic and are thus adapted 
to this hypoxic environment, thereby avoiding the excessive production of ATP through 
a less efficient generation of ATP [50, 52, 55, 212].  
We demonstrate that mitochondrial mass correlates with MMP in CB-derived CD34+ 
cells. This observation is supported by comparable results in other studies/cell lines 
[138, 213, 214]. We sorted cells by flow cytometry based on mitochondrial mass into 
CD34+ MitoHigh and CD34+ MitoLow populations to investigate their in vitro clonogenic 
capacity and in vivo repopulating potential. As expected, ATP levels and the expression 
of mitochondrial-specific genes were higher in CD34+ MitoHigh cells than in CD34+ 
MitoLow cells. Functionally, CD34+ MitoHigh cells exhibited higher in vitro clonogenic 
capacity, whereas the CD34+ MitoLow fraction displayed higher in vivo hematopoietic 
reconstitution upon transplantation in mice, thus demonstrating that the CD34+ MitoLow 
fraction is enriched in HSCs and the CD34+ MitoHigh fraction is enriched in progenitors. 
These data are in agreement with previous reports suggesting that HSCs are quiescent 
and contain less mitochondria, while proliferating HPCs have higher energetic demands 
[54, 207]. Importantly, mitochondrial segregation in CB CD34+ cells did not skew the 
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normal stem cell hematopoietic commitment as shown by similar colony forming units 
(CFU) composition in clonogenic assays and multilineage repopulating assays in vivo, 
revealing a similar cell fate despite differential mitochondrial mass.  
Cell surface marker expression allows the purification/isolation of HSCs with high 
efficiency. Additionally, several reports have defined a metabolic phenotype both in 
mouse and human HSPCs [51, 53, 54, 56, 215]. It has been demonstrated that LT-HSCs 
are present in a distinct population of cells characterized by low MMP and ATP, and 
use mainly glycolysis rather than OXPHOS for energy production. The glycolytic 
adaptation of HSCs is an evolutionary protective mechanism against oxidative damage 
originating from OXPHOS [51]. According to the surface markers described for HSCs 
(CD34+CD38-) and HPCs (CD34+CD38+) [7], the proportion of CD34+CD38- cells 
found in the CD34+ MitoLow population is higher than that found in the CD34+ MitoHigh 
population, supporting the concept that CD34+ MitoLow cells are enriched in HSC 
function. Along this line, Simsek et al. [54] described that Meis1 regulates HSC 
metabolism through transcriptional activation of Hif-1. HIF-1 is essential for the 
cellular and systemic response to reduced oxygen availability [61], and is highly 
expressed and critical in LT-HSCs [54, 60, 61, 63]. Consistent with these findings, we 
found that the expression of HIF-1α and MEIS1 was higher in CD34+ MitoLow cells than 
in CD34+ MitoHigh cells. 
Studies in vitro showed that CD34+ MitoLow cells differentiated slower than CD34+ 
MitoHigh cells, as revealed by a delayed kinetic of CD34 reduction. By day 15, all CD34+ 
cells had differentiated irrespective of mitochondrial mass and the expansion of CD34+-
derivatives was largely boosted, especially the derivatives of CD34+ MitoLow cells. 
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These results support the higher engraftment exhibited by CD34+ MitoLow cells because 
in vivo hematopoietic reconstitution is strictly regulated by a balance between self-
renewal and differentiation and a fast progenitor expansion at the moment of CD34 
antigen loss. An increase in mitochondrial biogenesis and function during stem cell 
differentiation has been reported previously [208] and is linked to higher ATP 
synthesis, which is necessary to maintain tissue/cell homeostasis. In line with this, 
following 15 days of expansion CD34+ MitoLow cells achieved mitochondrial adaptation 
and increased their ATP levels with subsequent up-regulation of the expression of the 
mitochondrial genes ND1 and COX2. This mitochondrial adaptation seems to occur 
through an increase in oxidative stress following the increase in ETC activity [109].  
Various studies link ROS levels to preservation of stem cell function, suggesting that 
high ROS levels are implicated in low HSC function. As expected, ROS levels were 
lower in the CD34+ MitoLow population than in CD34+ MitoHigh cells, indicating that 
CD34+ MitoLow cells are enriched in HSC function while the CD34+ MitoHigh are 
enriched in progenitor function. This confirms that CD34+ MitoLow cells mainly use 
glycolytic metabolism rather than OXPHOS as a mechanism to reduce the negative 
impact of the ROS production, which can lead to genomic instability [51].  Cancer cells 
evolved similarly to stem cells, adopting the Warburg effect, which prevents ROS 
generation and oxidative damage in aerobic conditions as an evolutionary adaptation 
advantage of cancer cells to their microenvironment [95, 96]. 
Mutations in genes involved in cellular metabolism and epigenetic regulation are 
implicated in the pathogenesis of hematopoietic malignancies via metabolic 
dysregulation [216, 217]. HIF-1 is required for maintenance of HSCs and cancer stem 
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cells, which share many functional and phenotype characteristics [218]. In cancer cells, 
HIF-1 seems to be the inductor of the Warburg effect [219] and recent studies have 
demonstrated that BCR-ABL positive cells and multiple myeloma cells display an up-
regulation of HIF-1, together with increased ROS generation and expression of glucose 
metabolism genes [220-223]. Although leukemic cells are highly glycolytic and release 
85% of glucose carbon as lactate, pyruvate and glutamine are important metabolic 
substrates, which are catabolized by pyruvate dehydrogenase (PDH) and glutamate 
dehydrogenase, respectively, allowing the utilization of glutamine-derived -
ketoglutarate in mitochondria via the -ketoglutarate dehydrogenase (KDH) complex 
[223]. Interestingly, cytoplasmic isocitrate dehydrogenase 1 (IDH1) and mitochondrial 
IDH2 are mutated in 15–20% of patients with acute myeloid leukemia, affecting redox 
metabolism, methylation and differentiation, among others. These data suggest that 
several targets involved in glycolytic metabolism, including HIF-1, PDH, KDH, IDH1 
and IDH2, could become therapeutic options to treat some hematopoietic malignances. 
Indeed, several leukemic cell lines have been treated with mitochondrial/OXPHOS 
inhibitors [224]. The study of leukemic cell metabolism is an important and promising 
area of research, but before any potential clinical translation it would be key to 
determine which specific group of patients would benefit from metabolic targeting 
therapies [223]. 
Over the last 20 years, umbilical CB has become an important source of HSCs both for 
research and clinical transplantation. However, in vitro and ex vivo expansion protocols 
for CB-derived HSC have been less than successful [211, 225, 226]. LT-HSCs mainly 
reside within the BM in specific niches that are physiologically hypoxic or anoxic as a 
result of low levels of glucose and oxygen [57, 58]. Metabolically controlled HSC 
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expansion may therefore rely on cell survival signals derived from the niche, such as 
RET signaling [227]. It has also been reported that BM-derived cells cultured in 
hypoxia had a superior repopulation activity than those cultured under normoxic 
conditions [212]. This therefore begs the question of whether we are using the most 
suitable in vitro conditions to expand CD34+ cells while also ensuring their genomic 
stability and function. For example, whereas HSCs reside in a hypoxic niche in vivo 
(<1% of oxygen), they are routinely maintained under normoxic conditions. As 
mentioned, HIF-1 is a key player in HSC metabolism and is essential for cellular and 
systemic responses to low oxygen availability and it seems to be crucial for the balance 
between self-renewal and differentiation of HSCs [51, 61, 228]. Under normoxic 
conditions, HIF-1 levels are reduced through oxygen-mediated degradation. HSCs 
increase their ROS generation by OXPHOS under normoxia and are forced to exit 
hypoxia-dependent quiescence [55, 59, 229]. ROS are also required for recovery after 
BM injury, increasing the expansion of committed progenitors [230]. These data 
support the notion that the BM niche, OXPHOS and ROS are linked to control 
proliferation, self-renewal and differentiation of HSCs.  
An interesting and open question currently is why HSCs are routinely maintained in the 
laboratory (worldwide) using high glucose-containing medium when by default they 
reside in low-glucose/glucose starvation conditions. In the BM niche, LT-HSCs are 
deprived of nutrients such as oxygen and glucose, which is the main carbon source of 
the cell to synthesize ATP and the key substrate for the proliferative PI3K-AKT-mTOR 
pathway [231]. The constitutive activation of AKT in HSCs causes accelerated 
proliferation/differentiation and depletion of HSCs [232, 233]. Moreover, genetic 
deletion of PTEN induces the constitutive activation of PI3K-AKT signaling, resulting 
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in increased proliferation, ultimately leading to HSC exhaustion [59]. Using nutrient-
sensing pathways, stem cells maintain energy production by collectively inhibiting key 
demanding processes including OXPHOS and promoting glycolysis. This interplay is 
key for the maintenance of stem cells in various tissues [59, 234, 235]. Taken together, 
it would be desirable to test for the most appropriate culture conditions to maintain 
HSCs in vitro and in vivo. 
II. A disease-specific iPSC model for CoQ10 deficiency: metabolic and 
developmental impact of a COQ4 mutation during differentiation of 
iPSCs into tissues affected by the disease. 
CoQ10 is a lipid-soluble molecule ubiquitous to cellular membranes that has essential 
functions in many cellular processes including energy/ATP production, where it 
shuttles electrons from CI and CII to CIII in the ETC [146, 150]. CoQ10 levels below 
50% of standard values are indicative of CoQ10 deficiency, which is a rare and 
heterogeneous group of metabolic/mitochondrial disorders (OMIM #607426) 
associated with a broad variety of genetic and clinical manifestation usually detected in 
the early years of life [157, 179]. CoQ10 deficiencies are commonly classified as either 
primary or secondary. Primary CoQ10 deficiency is an autosomal recessive syndrome 
that originates from mutations in genes responsible for CoQ10 biosynthesis (COQ genes 
or regulatory genes). The pathogenesis of secondary CoQ10 deficiency is less well 
studied but seems linked to assembly defects in OXPHOS complexes/metabolic 
pathways [157]. Primary CoQ10 deficiency usually affects the ETC due to the central 
role of CoQ10 as a mobile electron carrier between CI+III and CII+III, causing a 
mitochondrial phenotype. Given the high energy demand of neurons and muscle and 
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their dependence on OXPHOS, it is not surprising that mitochondrial diseases are 
commonly devastating to CNS and SkM as they are unable to synthesize sufficient 
quantities of ATP for completing physiological processes [154, 173, 174]. The only 
current treatment for this condition is the oral supplementation of CoQ10; however, 
there is a variable response to exogenous treatment and almost 50% of patients fail to 
respond to exogenous oral administration of CoQ10 [173, 236]. 
CoQ10 biosynthesis involves at least 15 COQ and regulator genes in a multienzymatic 
complex where COQ4 plays a central structural role [145]. Although several mutations 
have been identified in numerous genes involved in CoQ10 biosynthesis, there is no 
clear association between the genotype and the phenotype. That is, mutations in 
different genes may render the same clinical phenotype while distinct mutations in the 
same gene may render different phenotypes [153, 177]. It has been suggested that 
COQ4 mutations or haploinsuficiency causes CoQ10 deficiency associated with a broad 
phenotypic spectrum including encephalomyopathy, cerebellar atrophy, hypotonia, 
respiratory distress and neurological deterioration [175, 178].  
We identified a 4-year-old girl with the missense point mutation (c.483G>C; E161D) 
in COQ4 who displayed mitochondrial deficits affecting SkM with subsequent fatal 
rhabdomyolysis. This mutation was associated with low levels of CoQ10 and impaired 
biosynthesis and also ETC dysfunction. Mutant COQ4 fibroblasts presented a reduction 
in proliferative capacity linked to high levels of senescence-associated -galactosidase 
activity, reflecting the involvement of CoQ10 in pyrimidine synthesis and ETC 
dysfunction, which can produce ROS-mediated, oxidative damage/cellular senescence 
[129-131, 150, 158].   
V
I 
Mitochondria and stem cell function: 
from somatic cells to iPSC-based disease modeling 
 151 
 
Since their discovery in 1998, hESCs have been the PSCs of choice in stem cell research 
for applications such as cell therapy and disease modeling due to their potency and 
long-term proliferation potential. Nevertheless, they have been associated with ethical 
issues due to their prenatal/embryonic origin [24]. Since 2006, iPSCs represent a unique 
alternative to model human disease since they share similar properties to hESCs, such 
as pluripotency and infinite lifespan, while being free from ethical issues since 
embryonic tissue is not involved. iPSCs are particularly useful to study rare diseases 
with a known genetic alteration since the low prevalence of the disease challenges the 
recapitulation of a disease phenotype using primary cells from the patient. Our patient 
developed CoQ10 deficiency with fatal rhabdomyolysis associated with the E161D 
mutation in COQ4. Interestingly, a few years later the patient’s sibling developed a 
similar but weaker muscle phenotype (she ultimately died because of vascular cardiac 
failure) without mutations in genes involved in CoQ10 biosynthesis or CoQ10 
deficiency. To harness the full potential of patient-specific iPSCs, it would be crucial 
to unravel to what extent the specific genomic mutation is the sole pathogenic driver 
(or genomic modifier) contributing to the genotype-phenotype of the disease. A large 
number of studies have reported strategies to model disease phenotypes using iPSCs, 
including monogenic diseases and complex disorders such as Rett syndrome, Parkinson 
disease, cancer, Fanconi anemia, Huntington disease and Hutchinson-Gilford progeria 
syndrome, among others [1, 5, 15-17, 24, 89, 92, 186, 188-191, 194, 203]. One example 
of such an approach was recently reported for ALS [237]. Researchers discovered that 
iPSC-derived MN from an ALS patient displayed hyperexcitability with reduced 
survival, and that this phenotype could be corrected by a potassium channel agonist 
[237]. Another example was reported for Néstor-Guillermo progeria syndrome 
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(NGPS), where it has been demonstrated that NF-κB activation blocks iPSC generation. 
Accordingly, genetic and pharmacological NF-κB inhibition increases the 
reprogramming efficiency from premature-aged NGPS cells [193]. To the best of our 
knowledge, our work is the first to describe an iPSC-based model for CoQ10 deficiency.  
The CRISPR/Cas9 adaptive bacterial immunity system is a simple and versatile 
approach to engineer the eukaryote genome. It has successfully been used to 
modify/edit genes in monogenic disorders using patient-specific iPSCs [202-204, 206]. 
Here, we harnessed CRISPR/Cas9 technology to edit/correct a patient-derived iPSC 
line for the c483 G>C mutation in COQ4. The generation of isogenic cell lines allows 
the drawing of conclusions circumventing genetic and epigenetic variability. While the 
generation of off-target effects could be a side-effect of the CRISPR/Cas9 system, 
because it may generate a DSB in the DNA in an undesired region [201, 238], we 
verified the genome stability and the absence of off-target generation in our edited iPSC 
line without gross genetic aberrations. 
Levels of CoQ10 are usually measured as a diagnostic test in fibroblasts and muscle 
[171]; however, the levels of CoQ10 and its biosynthesis have not been reported in 
human PSCs. Here, we measured for the first time the levels of CoQ10 in PSC lines 
(iPSC/ESC). We characterized a range between ~150 and ~75 pmol of CoQ10/mg 
protein using a battery of control/healthy PSCs. These reference values allowed us to 
distinguish iPSCs with low levels of CoQ10, which could explain the key role of CoQ10 
in cellular/metabolic homeostasis. We observed that CoQ10 levels and biosynthesis in 
CQ4-iPSCs were lower than in Ctrl- and CQ4ed-iPSCs, demonstrating the cause-effect 
of the c.483 G>C mutation in CoQ10 biosynthesis. Interestingly, cell reprogramming 
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failed to re-establish CoQ10 levels/biosynthesis in CQ4-iPSCs, highlighting the 
evolutionary conserved role of CoQ10 in cellular homeostasis involving nucleotide 
synthesis and OXPHOS regulation. Moreover, in order to synthesize an equivalent 
amount of ATP, CQ4-iPSCs required 2-fold higher levels of OCR and ECAR rates as 
an indirect measure of OXPHOS and glycolysis, respectively. This increase in energetic 
metabolism is likely related to the electron leak due to the reduction of CoQ10 in the 
ETC, which causes a mitochondrial dysfunction. Leaking of protons, which were 
observed in the OCR, is an indirect measure related to electron leak [239]. Overall, 
these data suggest an altered metabolism in patient iPSCs, where COQ10 plays a central 
role stabilizing electrons and its deficiency impairs the proper functioning of the ETC. 
This dysfunction was reversed after the correction of the c.483 G>C mutation. 
Neurological manifestations are very common in CoQ10-deficient patients [157, 172]. 
We therefore differentiated iPSCs towards the neural lineage using well-established 
protocols for DAns [27] and MNs [29]. We induced neural differentiation of iPSCs 
using dual SMAD inhibition, which allows differentiation into early neuroectoderm by 
blockage of ALKs signaling pathways of BMP (LDN193189) and TGFβ (SB431542), 
reducing the complexity of neural differentiation [82, 240]. We obtained between 15–
25% of TUJ+ neurons and less than 10% of these showed a DAn or MN phenotype. 
Although, our data revealed a high percentage of neural differentiation, current 
neuronal differentiation protocols need to be largely improved to attain a higher 
proportion of differentiated cells, which would allow functional electrophysiological 
and metabolic assays on iPSC-neural derivatives. The fact the iPSC-derived neurons 
failed to reveal a phenotype when compared with control iPSCs is in line with the 
patient phenotype, which was free from severe neurological symptoms. These data 
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further validate our iPSC model as a bona fide system to reproduce the main features 
of a given disease.  
Fatal rhabdomyolysis was the main clinical alteration in our patient. Because of this, 
we differentiated iPSCs into SkM following the protocol based on PAX7-mediated 
differentiation published by the Perlingeiro laboratory [89]. We first generated 
transgenic iPSC lines by lentiviral transduction with the inducible PAX7-GFP plasmid. 
Myogenesis was then induced by doxycycline induction of PAX7. After embryoid body 
differentiation, PAX7+ myogenic progenitors were sorted based on the expression of 
GFP and cultured under myogenic conditions to further promote muscle myogenic 
maturation. CQ4-PAX7+ myogenic precursors had high levels of ROS, possibly 
underlying the increased senescence and the reduced/impaired proliferation potential 
of these cells versus their edited counterparts. SkM maturation was assessed by 
analyzing the percentage of MYH1+ cells and measuring creatine kinase activity, which 
are both specific markers of SkM cells. We found that CQ4-PAX7+ progenitors 
displayed a lower capacity of SkM maturation than their edited counterparts, which was 
accompanied by a dysregulated expression of myogenic differentiation markers 
implying a possible blockage of differentiation. We therefore assessed mitochondrial 
dysfunction in iPSC-derived muscle progenitors by examining mitochondrial dynamics 
and ETC activity. These studies confirmed a reduction in CI+III activity and also 
abnormalities in mitochondrial morphology. Collectively, these results establish the 
utility of an iPSC-based disease model to study genotype-phenotype association, 
wherein the c.483 G>C mutation faithfully reproduces disease-associated SkM 
functional and metabolic defects. The combination of altered mitochondrial dynamics 
and reduced ETC may contribute to the vulnerability of muscle maturation. 
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In summary, we demonstrate that iPSCs generated from our patient differentiate 
normally into DAn and MNs using well-established protocols [27, 29], while 
differentiation to SkM was compromised. Patient-specific iPSCs also reproduced the 
metabolic defects observed in the COQ4 mutated cells, and these metabolic and 
phenotypic defects were reversed when the COQ4 mutation was genetically corrected. 
The CoQ10 deficiency model here established represents a unique system for studying 
CoQ10 pathogenesis, which we believe will facilitate the discovery of novel therapeutic 
drugs and will provide valuable information about the molecular/genetic basis of 
responsiveness to CoQ10 treatment.  
Human PSCs represent a unique tool for cell therapy strategies and disease modeling 
because of their ability for self-renewal and differentiation into any tissue of the three 
embryonic germ layers. The robustness of this system is demonstrated by the use of 
PSC-derived cells in several clinical applications [33], listed in Table 1. For example, 
in 2014 the first ever clinical trial to test a PSC-based treatment for type 1 diabetes 
mellitus was initiated. A subcutaneous implantable device containing hESC-derived 
pancreatic endoderm cells was explored for treatment of diabetes [241-243]. 
Nevertheless, the most common type of clinical trial (currently standing at nine) testing 
PSC-based therapies predominantly focuses on a therapeutic window for retinal 
generation. The eye has many characteristics that make it an attractive organ for clinical 
trials: it has an immunoprivileged nature, it represents an isolated environment where 
the transplanted cells are restrained, it is accessible for injection and it can be non-
invasively monitored by visualization for the detection of internal tissue. The 
generation of retinal pigment cells from PSCs may soon be a treatment for the 
degeneration of light-sensing photoreceptor cells and the retinal pigment epithelium in 
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the eye, and is being explored in several clinical trials [244-246]. As another example, 
grafts of PSC-derived cardiac cells may also provide functional restoration of areas of 
weakened or ischemic heart tissue. Preclinical studies demonstrated that the 
administration of hESC-derived cardiac progenitors improves overall cardiac function, 
however, the engrafted cells were undetectable after four months, suggesting that their 
role in improving cardiac function may have been to enhance the endogenous repair 
processes [31, 247]. In addition, a clinical trial using hESC-derived oligodendrocytes 
was initially launched early in 2009 to treat spinal cord injuries, which consisted in the 
administration of oligodendrocyte progenitor cells to enhance remyelination and 
improve motor function. The trial was abandoned in 2011, although a new clinical trial 
was subsequently initiated [248]. Patients with hematopoietic disorders or suffering 
blood loss require continual transfusions but, unfortunately, blood derivatives obtained 
from donors are only accessible in limited quantities and have a very short half-life. 
The generation of a donor-independent system capable of providing constant and 
sufficiently large numbers of functional cells would therefore be an important step 
forward in transfusion medicine. Red blood cells and platelets can be generated from 
hESC/iPSCs, but this is currently an inefficient process [249-255]. Other blood cell 
types including T cells, HSCs and dendritic cells have yet to be successfully generated 
[25, 256-258]. Establishing and improving protocols to differentiate these cell types 
from PSCs may become a future therapeutic option for treating blood disorders. 
Notwithstanding these challenges, current clinical trials have demonstrated the 
feasibility of PSC-based cell therapies, although more work on differentiation, 
molecular and genetic mechanisms are needed to deliver specific and homogeneous cell 
populations with fully functionality in vivo. 
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Table 1. hESC and iPSC-based products in clinical trials 
Cell type Trial location Disease Reference 
hESC-derived RPE USA Dry AMD NCT01344993 
hESC-derived RPE USA Stargard NCT01345006 
hESC-derived RPE UK Stargard NCT01469832 
hESC-derived RPE Korea Dry AMD NCT01674829 
hESC-derived RPE Korea Stargard NCT01625559 
hESC-derived RPE USA MMD NCT02122159 
hiPSC-derived RPE Japan Wet AMD [244] 
hESC-derived RPE UK Wet AMD NCT01691261 
hESC-derived RPE Israel Dry AMD NCT02286089 
hESC-derived CD15+ISL-1+ 
cardiac progenitors  
France 
Severe heart 
failure 
NCT02057900 
hESC-derived pancreatic 
endoderm  USA Type I diabetes NCT02239354 
hESC-derived oligodendrocyte 
progenitors  USA 
Spinal cord 
injury 
[248] 
AMD: age-related macular degeneration; ISL-1: Islet-1; MMD: myopic macular 
degeneration; RPE: retinal pigment epithelium.   
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Regarding the first part of the PhD thesis, we conclude that: 
1. There is a strong correlation between mitochondrial mass and mitochondrial 
function in cord blood-derived CD34+ cells.  
2. The CD34+ MitoHigh fraction is enriched in progenitor function, as revealed by 
higher clonogenic capacity. 
3. The CD34+ MitoLow fraction is enriched in stem cell function, as revealed by 
an increased in vivo hematopoietic reconstitution.  
Regarding the second part of the thesis, we conclude that: 
4. Induced pluripotent stem cells from a CoQ10 deficient patient harboring a 
COQ4 mutation have been generated, characterized and CRISPR/Cas9 edited. 
5. The COQ4 mutation directly influences CoQ10 biosynthesis and concentration 
causing a mitochondrial dysfunction in CQ4-iPSC. 
6. The COQ4 mutation does not impair the in vitro differentiation of CQ4-iPSCs 
into either midbrain dopaminergic neurons or spinal motor neurons. 
7. The COQ4 mutation negatively alters the differentiation towards skeletal 
muscle linked to decreased mitochondrial and metabolic function as revealed 
by a reduced ETC activity and mitochondrial dynamics.  
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